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ABSTRACT
The American University in Cairo

Evaluation of Rapid Low-Cost Colorimetric Methods for
Diagnosis of Multidrug-resistant Tuberculosis in LimitedResource Settings
BY: Mai M. H. Mansour
Under the supervision of Dr. Hassan M. E. Azzazy and Dr. Moustafa Abdel Fadeel
One third of the world’s population is currently infected with tuberculosis (TB), a
consuming airborne disease whose main causative agent is Mycobacterium
tuberculosis. The majority of these patients are found in the world’s poorest areas.
Treatment of TB is a lengthy and demanding process utilizing a cocktail of powerful
drugs; however, multidrug resistant TB (MDR-TB) strains, defined by resistance to
both isoniazid (INH) and rifampicin (RIF), are now emerging worldwide and
threatening disease control efforts. The major problem facing efforts to combat MDRTB spread is its early detection. Conventional fairly affordable methods for drug
resistance detection are based on solid culture and are highly time consuming (3 -6
weeks in addition to initial pathogen culturing). On the other hand, the more rapid
liquid culture-based automated systems are costly to set up and maintain while the
very rapid molecular assays (hours to few days) are simply too complex and
unaffordable and non-sustainable in limited resource settings. The objective of this
work was to evaluate the performance of two liquid culture-based colorimetric assays
for detection of drug resistance; nitrate reducate assay (NRA) and colorimetric redox
indicator (CRI) methods for detection of MDR-TB. The assays were tested on
mycobacterial isolates from Egyptian patients and their performance was compared
with microscopic observation drug susceptibility assay (MODS) and the commercial
automated culture system MGIT 960. Concordance was 96.7% for CRI and 93.3%, at
almost one-tenth of the MGIT cost, and close to that of MODS without the need for
an inverted microscope. The NRA format used in this study is more convenient and
higher in throughput than the initially developed format. Additionally, DNA was
extracted from the mycobacterial isolates and16S rDNA was amplified and sequenced
to gain insight on the molecular diversity of Egyptian strains. Moreover, the
molecular basis of strain resistance was investigated by DNA sequencing of the genes
most commonly containing resistance conferring mutations. Analysis of the 16S
rDNA sequencing results confirmed the identity of the samples as mycobacterium
tuberculosis and suggested possible presence of two different strains. On the other
hand, the analysis of the resistance related genes found common resistance conferring
mutations in the MDR samples.
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1. Background and Review of Literature
1.1.

Tuberculosis

Tuberculosis (TB), once known as the “white plague” and “consumption”, is one of
the oldest known diseases. In addition to plaguing medieval and renaissance Europe,
TB has been traced back and documented in ancient civilizations including Greek,
Egyptian, and Pervian. To date TB remains a global health problem and pandemic,
presenting significant challenges in both diagnosis and treatment

[1]. The air-

transmitted disease is caused primarily by the bacterium, Mycobacterium tuberculosis
(MTB). TB was declared a global emergency in 1993 by the World Health
Organization (WHO) and currently affects about one third of the world’s population,
with 8-9 million new TB cases annually. The estimated death toll in 2010 alone was
1.1 million among human immunodeficiency virus (HIV)-negative people, in addition
to another 0.35 million among HIV-infected individuals [2-5]. TB remains a
particularly alarming problem in sub-Saharan Africa where there are high co-infection
rates with HIV (50% of TB patients in southern Africa are HIV-positive [6]). Overall
globally, 13% of TB cases occur among HIV-positive individuals. There is only one
available vaccine; the Bacillus Calmette–Guérin (BCG), a live attenuated vaccine,
which has been in use since the 1920s, and whose actual benefits are questionable. It
has a highly variable efficacy (reportedly 0-80%) and does not prevent occurrence of
TB infection. It rather protects against severe forms of TB such as miliary TB,
particularly in infants, thereby preventing only about 5% of deaths that could be
averted via vaccination [7-11]. Despite the fact that incidence rates of TB have been
declining over the past decade, TB remains an active global threat. It must also be
noted that the actual TB burden extends beyond the direct death and has an extensive
social impact, which is visible in the fact that about 10 million children were
orphaned because of TB in 2009 [3]. The poorest of countries are typically hit the
hardest by TB as the low standards of living, overcrowdness and poor healthcare
facilities are direct causes of high infection rates, particularly in areas with high HIV
prevalence [12]. Additionally, over the next decade it is estimated that the economic
consequences of TB will claim $1 to $3 trillion, catastrophic figure for nations whose
people get by with under $2 daily [13]. Asia and Africa bear the worst of the TB
impact where they have 55% and 30 % of all TB cases worldwide, respectively
(Figure 1). Egypt-specific TB statistics are presented in table 1. Notably, in 2007
1

government expenditure on health in Africa was $34 per capita and in Southeast Asia,
home to 30% of the world’s poor, it was only $15 per capita. Moreover, almost 80%
of all TB cases globally are found in 22 countries known as the high burden countries
(HBCs) [3, 11, 14-15]. These countries include the 7 countries with the highest
hunger rates globally, according to the United Nations Food and Agriculture
Organization (FAO) [16]. Low socioeconomic conditions, undernourishment, and
poor hygiene conditions aggravate the problems of TB, and great concordance
between TB incidence rates regions and FAO hunger regions are a demonstration of
this fact. Furthermore, children constitute about 15-20% of TB cases in endemic
regions [3].

1.2.

Mycobacterium tuberculosis (MTB)

Mycobacterium tuberculosis (MTB) is a member of the Mycobacterium genus of
acid-fast bacteria, and was first discovered in 1882 by Robert Koch. MTB organisms
are intracellular pathogens which are aerobic slow-growing (18-24 hr generation time)
non-motile rod shaped bacilli, measuring 0.5 x 3 µm. It is the primary TB-causing
member in the mycobacteria, although a few other members are capable of causing
tuberculosis. These are known collectively as M. tuberculosis complex (MTBC) and
include M. bovis (causes TB in cattle), M. bovis BCG (the attenuated strain used in
vaccines), M. africanum (less pathogenic than MTB, causes TB-like symptoms, found
mainly in West Africa), and M. canettii (found mainly in Horn of Africa). There is
also M. microti, which is seldom the culprit in human TB cases but causes the disease
in voles, in addition to M. caprae and M. pinnipedi, which are causative agents of TB
in goats and deer, and seals, respectively; however, human infection has been
demonstrated possible [8, 17-18].
Mycobacteria are characterized by having peptidoglycan cell walls with
exceptionally high lipid content, mainly mycolic acid (Figure 2), and thus cannot
retain any conventional stains such as the basic aniline dye Gram stain. This means
they cannot be classified as either Gram-positive or Gram-negative. However, they
can be stained with basic lipid-soluble fuschin dyes as they cannot be decolorized
with acidified alcohol containing 3% HCl, a property known acid-fastness [1, 7-8, 1719]. The exceptional cell wall structure of MTB is a key virulence factor, as this
hydrophobic cell wall is impermeable to many antibiotics, and contains channels and
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porins that pump out drugs. Also, this lipid-rich rigid cell wall containing the
carbohydrate lipoarabinomannan allows MTB to survive within the patients’
macrophages that engulf the bacilli [18-21].

1.3.

Transmission and pathogenesis of tuberculosis

TB is spread by droplet inhalation and merely 1-3 bacilli suffice for infection if
inhaled [22]. The outcome of infection can be elimination of the bacilli and infection
clearance, failure to control the infection and development of active symptomatic TB,
or control of infection by the immune system without clearance of tubercle bacilli. In
the latter case the patient is noninfective and exhibits no symptoms, however, he/she
is bearer of dormant bacilli which may be reactivated if the person’s immunity is
severely compromised e.g. due to HIV infection or uncontrolled sepsis or diabetes
mellitus [7, 19]. Typically less than 10% of individuals who become infected with TB
bacilli will develop an active infection. Depending on degree of immunocompetency,
this value can reach 30%, and coinfection with HIV makes progression to active TB
disease 21-34 times more likely, and if active TB is left untreated, fatality is estimated
to be 50% [8, 14, 22-23].
When infective droplets containing MTB are inhaled, a portion may be
eradicated by the mucociliary systems in the airways. The evading bacilli that reach
the lungs are engulfed by macrophages as an infection containment defense.
However, MTB possesses an extraordinary ability to persist within the macrophages
and counteracts their destruction mechanisms. The first line of defense for MTB
against the destructive environment inside macrophages is the sturdy cell wall. On
another front, MTB counteracts the acidification process initiated by the
macrophages, thereby changing the pH within the macrophage from the deadly 4.5-5,
to a near neutral 6.4. Moreover, the entire metabolic profile of MTB alters so as favor
survival within the hostile macrophage environment with limited nutrients [7, 18-19].
The accumulation of macrophages and T-lymphocytes around the tubercle
bacilli creates a granuloma in this region. Necrosis then sets in and gradually the
bacilli are trapped within the characteristic lesions in a microenvironment with low
oxygen, pH, and nutrients. The bacilli thus minimize all their metabolic functions and
go into a non-replicative dormant state, and latent TB is established. If the patient
immune system is not sufficiently strong, or if latent TB is reactivated, the bacilli
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cannot be contained within the granulomas, which burst open and the bacilli spread.
They can spread to the alveoli and cause pulmonary TB, or the infected macrophages
can take the bacilli to other organs causing extrapulmonary TB (20% of all TB cases)
e.g. lymphatic TB. The clinical symptoms of active TB are rather non specific, they
include fatigue, night chills and sweats, malaise, progressive weight loss, low-grade
fever, and coughing in pulmonary TB where sputum is usually tainted with blood [7,
12, 18-19].

1.4.

Drug-resistant tuberculosis

MTB has an intrinsic resistance to a variety of antibiotics by virtue of its exceptional
cell wall structure which also include multiple efflux mechanisms to counteract drug
and antibiotics, in addition to -lactamase activity. Additionally, drug resistance of
TB can either be primary or acquired, table 2 provides definitions for key terms
related to drug resistance [21, 24], and multiple factors contribute to the development
of drug resistance in a TB isolate. Resistance to a single drug can be the outcome of a
spontaneous mutation in the respective resistance-conferring gene, an event which
occurs in wild MTB strains every 10 6 to 108 replications. For the two main anti-TB
drugs isoniazid (INH) and rifampicin (RIF), the rate of
-8

conferring mutations are 2.56x10 and 2.25x10

-10

spontaneous resistance-

, respectively [25]. The use of drug

combinations in TB therapy reduces the likelihood of emergence of resistance, as the
risk of a stain harboring two resistance mutations is less than 10 -18 [21]. The primary
cause of acquired TB drug resistance is prior unsuccessful or incomplete therapy, and
thus drug resistance is significantly more likely in retreatment patients, who represent
about 13% of notified TB cases worldwide [21, 26].
An issue with global ramifications is the rise of the incidence of drugresistance in TB, particularly multidrug-resistant TB (MDR-TB) strains worldwide.
MDR-TB strains demonstrate resistance to both rifampicin (RIF) and isoniazid (INH),
the two main drugs of first line anti-TB antibiotics [27-30]. MDR-TB strains currently
infect about 50 million patients worldwide [7, 31], with almost 500,000 new cases
annually [32]. MDR-TB cases account for about 2.9% of all new TB cases worldwide
[25] with the prevalence of MDR-TB in retreatment cases differing significantly
between countries (30% to 80% [33]), with the countries of the former Soviet Union
having a particularly significant increase in incidence of MDR-TB [4]. Figure 3
4

illustrates the global distribution of proportion of MDR-TB cases among notified new
cases of TB. 85% of the global cases of MDR-TB can be found in 27 HBCs, with
China and India alone comprising half of the global MDR-TB burden [34]. This
makes up a combined total of 36 HBCs for TB and MDR-TB [3]. Another alarming
fact is that an estimated 5-7% of the annual new MDR cases become extended drugresistant TB (XDR-TB). XDR-TB strains are additionally resistant to a fluorquinolone
and at least one of the injectable antibiotics: amikacin, kanamycin, and capreomycin
[21].
Despite presenting a significant challenge, MDR-TB is treatable with secondline drugs (e.g. fluoroquinolones). However, early diagnosis is crucial for proper
management of the patient [33, 35]. In 2008, 150,000 lives were lost to MDR-TB,
mainly because the patients did not receive the required second-line drugs [25]. The
fact that only about 7% of global MDR-TB cases are detected is extremely alarming
[36]. In Egypt, less than 3% of newly diagnosed MTB cases are classified as MDRTB, however, this figures rises to about 38% among retreatment cases [34]. Despite
the increase in number of MDR-TB cases receiving treatment in 2010, they still
account for a meager 16% of the notified MDR-TB cases that year. This is not
surprising when considering that in the majority of countries less than 5% of both new
and retreatment TB patients were tested for presence of MDR-TB strains [3].

1.5.

Genome of Mycobacterium tuberculosis

MTB is noted for genetic homogeneity, and the genome of the reference virulent
strain H37Rv was sequenced in 1998 and is about 4.4 Mb in size, with a high GC
content (65.6%), and 4,000 genes [5, 8]. This is currently the only universal control
available for drug sensitivity testing (DST), as a characterized pathogenic pansusceptible strain [37]. The phenotypic and virulence variations observed among
different MTB strains may be molecularly attributed to polymorphic genomic ‘regions
of difference’ (RD), which measure about 0.5 kb [5, 8]. Correlation between
expression levels of RD1 antigens with strain virulence has been demonstrated with
the BCG vaccination strain, and the deletion of RD1 has been shown to be a key
factor in the loss of strain pathogenicity [8, 38-39]. Certain RD loci, can also be of
utility in strain lineage identification, such as MTB deleted region 1 (TbD1) whose
presence or absence helps define MTB lineages [8].
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The currently circulating strains of MTBC are believed to have emerged from
a common ancestor, M. prototuberculosis, 40,000 years ago in East Africa, then
spread in concordance with human population motion. Then about 20,000 years ago
two lineages emerged, one which became exclusive to human infection and the other
caused animal infections [8, 40]. Currently circulating MTB strains comprise six
major clades with geographical association. Also, there is strain variability in disease
development and interaction with host immune system [1, 41-42]. The Beijing strain,
the most thriving current strain which showed about 500-fold population expansion
almost 180 year ago, along with the Indo-Oceanic lineage are significantly more
likely to cause disseminated tuberculosis and meningitis compared to European
lineage strains. Also, multiple cases of drug resistance were found to be associated
with strains belonging to W or W-like families, and animal model studies highlight the
association of W-Beijing strain with high virulence and increased dissemination, and
early mortality [12, 40-42]. Figure 4 illustrates geographical strain migration.
Regarding Egypt, there is no clear data on the predominant circulating strains
of MTB and the most recent study found, only indicates that there is unexpectedly
high proportion of Manu lineage strains, but does not provide details of the circulating
strains [43]. Such information is important not only for epidemiological analysis and
infection tracing to aid disease control efforts , but also due to the presence of
evidence that there is some correlation between genotypes and disease progression
[44]. This is particularly noting that Egypt is expected to have mixed lineages in the
circulating strains (Figure 4).

1.6.

Treatment of tuberculosis

The availability of effective drugs make TB a manageable disease, however, the cost,
both monetary and humanitarian, is by no means small. Treatment of TB is a lengthy
and demanding process. A typical treatment course would last 24-36 weeks using a
combination of drugs, which is one contribution to noncompliance of patients and
premature interruption of therapy, leading to relapse and possible emergence of drug
resistance

[24-25]. The emergence of MDR-TB and XDR-TB along with HIV

coinfection has compounded the treatment challenges. Treatment of MDR-TB
requires a minimum of 18-24 months of therapy and has 60-70% success rates and
mortality rates range from 10-15%, and can cost up to 200 times more than drug-
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sensitive TB [25, 45]. On the scale of a nation’s economy, about $4 billion are needed
each year to sustain the infrastructure required for treatment of TB patients, which is a
substantial financial burden on the struggling economies of developing low-income
countries [13]. However, the use of the WHO directly observed treatment short course
(DOTS) strategy between 1995 and 2010 resulted in 7 million saved lives and
successful treatment of 46 million patients [3].
The first anti-TB to be discovered was streptomycin (SM) in 1944. However,
due to extensive SM monotherapy, resistance developed rapidly to it [1, 21, 46]. The
first line anti-TB drugs comprise isoniazid (INH), rifampcin (RIF), pyrazinamide
(PZA), ethambutol (ETH), and streptomycin (SM), where INH and RIF are the two
most potent drugs. Table 3 describes these drugs and their actions, while their
chemical structures are shown in figure 5. INH, the first oral anti-TB drug, was first
discovered in 1952, and an INH monotherapy is favored for the latent TB treatment
[1, 45-46]. The discovery of rifamycin compounds in 1957, strengthened the anti-TB
arsenal with another oral drug; RIF [1, 24]. RIF must always be given in conjunction
with another potent antimycobacterial as resistance readily emerges to it [26], and
resistance to rifampicin is sometimes considered a marker for MDR [47]. Table 4
presents the molecular basis of resistance to first-line drugs.
The standard treatment regimen for new TB patients is 2 months of INH,
ETH, RIF, and PZA, followed by 4 months of INH, RIF, and ETH. Drugs are
administered 5 to 7 times weekly in most regimens. As for retreatment patients, who
made up 13% of TB notifications in 2007, DST is recommended prior to therapy
initiation and should be the guide for therapy design [26, 45]. However, if DST is not
promptly available, the general approach involves treatment duration of about 18-21
months. This involves use of at least 4 drugs to which are likely to be effective as
resistance to them is not expected, including an injectable for 7 months followed by a
minimum of 3 likely effective drugs. Drugs with expected cross-resistance must be
excluded [25-26]. The need for using the drugs cocktail for TB treatment is the need
to eliminate tubercle bacilli at different metabolic and growth phases, thereby each
drug has a different role in treatment [25, 46, 48], as shown in table 3. Figure 6
illustrates the target of different TB drugs of the different phases of TB in infection.
In case of intolerance to INH or resistance, 4 month of RIF is an alternative in
such cases [45]. INH resistance accounts for almost half of all cases of TB drug
resistance, amounting to almost 7.4% of all resistance cases. Additionally, it was
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found that monoresistance to INH further aggravates the problem of MDR-TB, as it is
a primary risk factor for acquired rifampicin (RIF) resistance [25]. The frequency of
INH resistance in vitro is 1 in 105 -106 bacilli [46]. Isolate susceptibility to both RIF
and INH makes detection of ETH or SM resistance inconsequential, as treatment
regimen will not require modification, and DST for these drugs can only be performed
if specifically relevant to a particular patient treatment [49]. In regions where
prevalence of INH resistance is more than 10%, for new TB patients, a 2 month
intensive treatment phase using INH, RIF, PZA, and ETH followed by a continuation
phase including ETH, plus INH and RIF. Also, the standard recommendation for
isoniazid monoresistance, despite uncertainty of effectiveness, is 2 months RIF, ETH,
and PZA, followed by 8 months RIF and ETH [25].

1.7.

Diagnosis of tuberculosis infection
The main strategies for TB diagnosis have not changed much for decades, and

in most regions with high TB burden.The primary detection methods of active
infection rely on finding the TB bacilli in patient sputum smears. This is a relatively
simple, fast, low cost approach that dates back to more than 100 years, however, and
yet it misses about 30-35% of positive cases [3, 31]. Culture identification is
recommended for smear negative samples and DST, and chest x-ray may be
performed sometimes in presence of suggestive clinical symptoms to aid diagnosis
[3]. The inadequate performance of the current diagnostic strategies is reflected by the
global detection rate of 62%, falling short of the 2005 goal of 70% set by the World
Health Assembly, the decision-making entity of the WHO [50]. The magnitude of
resource limitation for TB diagnosis is demonstrated by the fact that still 8 of the 22
HBCs lack the WHO recommended 1 microscopy center per 100,000 population [3].
Table 5 summarizes the main diagnostic strategies available for TB and their
limitations.

1.7.1. Phenotypic and biochemical identification
1.7.1.1.Microscopic examination
Smear microscopy relies on the examination of sputum smears for acid-fast bacilli
(AFB) stained using acid-fast Ziehl Neelsen (ZN) stain (primary dye is carbolfuschin)
(figure 7). For detection of positive samples, a minimum of 300 microscopic fields
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must be observed, and AFB smear microscopy requires the presence of at least 5,000
to 10,000 bacilli per mL of sputum, a lower bacillary load would be missed. AFB
smear microscopy is useful for detection of active TB infection as non-viable bacilli
with damaged cell walls may lack the acid-fastness upon which the staining is based
[4, 17, 48, 51-53]. The recommended procedure for use of smear microscopy to detect
pulmonary TB involves the examination of two sputum smears, and morning
collection specimens are preferred [3, 11].
The detection rates are highly variable ranging from 20-80%. Detection rates
below 20% are observed in HIV patients, and extrapulmonary TB, and MDR strains
cannot be detected, and almost 60% of all TB notifications are either smear-negative
or extrapulmonary cases. Also, AFB smears cannot differentiate MTB from
nontuberculous mycobacteria (NTMs) with similar looking bacilli, which can pose a
problem in area where TB is not endemic [3-4, 27, 53]. An estimated minimum 17%
of new infections are acquired from others who tested smear-negative [24]. One
approach which is suggested to improve AFB smear sensitivity is sputum
concentration prior to examination either by passive sedimentation or treatment with
bleach or ammonium sulphate, followed by centrifugation [11]. 11-26% improvement
in sensitivity has been reported when the latter method was used [54].
A number of recent improvements have been developed to enhance the
performance of smear microscopy. One of which is the use auramine/rhodamine
fluorescent dyes for staining smears and the use of fluorescence microscopes for
examination. Despite providing a notable enhancement in sensitivity, throughput, and
speed of detection, this modification also comes with a significant increase in cost, as
the stain, the microscopes and their bulbs are expensive. A possible compromise
between cost and performance advantages of fluorescence microscopy may be
provided by the newly developed light-emitting diode (LED) microscopes, which are
cheaper than regular fluorescence microscopes and can emit regular white light as
well as fluorescence wavelengths. The use of LED smear microscopy has been
endorsed by the WHO, and several commercial products for TB diagnosis are now
available [3, 11, 52, 55].

1.7.1.2. Immunological assays
The main utility of immunological assays in TB diagnosis is screening for latent TB
infection. One of the oldest and most widely used assays is the tuberculin skin test
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(TST), also known as the Mantoux test. This test involves intradermal injection of TB
purified protein derivative (PPD) and then examining the area of injection after 2 -3
days for induration. TST detects the cell-mediated immune reaction to the infection,
and the cut off diameter of the induration for a positive reaction depends on the risk
group to which the patient belongs. False positive results can be observed in
previously vaccinated or exposed individuals, and cross reaction with other
mycobacteria, as some antigenic components of PPD are conserved among
mycobacteria. Also, false negatives are observed in case of immunocompromised
patients and those with recent active infection [2, 12, 14, 19].
Another immunological assay; the interferon gamma release assay (IGRA),
measures interferon gamma release by T-cells in response to exposure to certain MTB
antigens. Initially PPD was used and then other proteins with higher specificity to
MTB came into use instead, which are encoded by genes in the RD1 region of the
genome e.g. early secreted antigenic target 6 (ESAT-6) [2, 12]. This region is very
specific to MTB as it is not found in the BCG vaccine strain and most NTMs, and
IGRAs have demonstrated superior specificity to TST and similar sensitivity [2, 8,
56]. However, clinical performance of IGRAs is inadequate for detection of
extrapulmonary TB. Three commercial FDA-approved IGRAs are available; T-SPOT
TB test (Oxford Immunotech, Abingdon, UK), QuantiFERON-TB Gold (Cellestis
Ltd, Carnegie, Australia), and the QuantiFERON-TB Gold in tube (Cellestis Ltd,
Carnegie, Australia). After demonstration of significantly superior performance to
TST, IGRAs are currently the only available methodology for accurate detection of
latent TB infection, a critical determination for the success of disease control efforts
[2, 12, 19, 52, 56-58].
On a different front, immunological assays are being developed in attempt to
provide fast, direct, non-invasive diagnosis of TB by detection of relative antigens in
urine. This could also mean the possibility to develop point-of-care tests which would
greatly benefit low-income regions with endemic TB. Another important advantage of
detection of TB antigens is avoiding false results due to modulations of the host
immune response as is the case with HIV patients when testing for antibodies.
Additionally such antigens are generally associated with actively replicating
pathogens and thus allow distinguishing between active and latent TB infections [6,
50, 59-60].
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Lipoarabinomannan (LAM) is a mycobacterial cell wall glycolipid which was
originally found in patients’ serum, but was later found to be excreted in urine. LAM
is currently detected using enzyme-linked immunosorbent assay (ELISA) and is
particularly sensitive in HIV-positive patients and in smear-positive patients.
Nevertheless, the overall sensitivity and specificity of LAM detection assays are not
yet adequate for conclusive diagnosis of active TB infection [50, 59-60]. However,
LAM urine testing combined with smear microscopy can be of value for TB detection
in areas of high HIV prevalence [6]. In addition to LAM, a number of other urine
antigens are being investigated. These include MTB ornithine carboamyltransferase,
phosphoadenosine phosphosulphate reductase, homoserine O-acetyltransferase, and
MoaA-related protein as markers of active pulmonary TB infection [31, 61].

1.7.1.3. Culture methods
The current gold standard for diagnosis of MTB infection is bacterial culture, which is
very sensitive, however, it is extremely time consuming (typically 3-4 weeks), and
has substantial infrastructure and biosafety requirements. Solid media include the
conventional and popular egg-based Lowenstein Jenssen (LJ), and the agar-based
Middlebrook 7H10, and the newly developed TK medium [4, 18, 48, 52]. LJ cultures
are highly sensitive and can detect as few as 10-100 bacilli, and figure 8 shows the
typical colony morphology of MTB grown on them. The TK medium, which has
comparable sensitivity to LJ, has the advantage of having a colorimetric indicator
incorporated within it, which indicates the mycobacterial growth even prior to colony
visualization. However, larger studies are needed for performance validation [17-18,
58, 62]. Sputum specimens to be cultured are first decontaminated and liquefied using
N-acetyl-L-cysteine (NALC)-NaOH (2%) treatment, and then planted on the culture
medium. NALC is a mucolytic agent while the NaOH kills normal flora in the
sputum. The treatment includes a centrifugation for concentration of bacilli.However,
overtreatment of the sputum using this approach e.g. using excessive reagent volume
with respect to the sample volume, can kill almost one third of the mycobacteria in the
clinical specimen [11, 18, 58].
Conventional

culture

methods

also

incorporate

subsequent

multiple

biochemical properties allow differentiation of MTB from other mycobacteria. MTB
has the capacity to reduce niacin and nitrate but yields a negative result with catalase,
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tellurite, and thiophene-2-carboxylic acid hydrazide (TCH) tests. Additionally,
identified and differentiated from NTM using media that contains para-nitrobenzoic
acid (PNB), which inhibits MTB growth [18, 63].
The development of liquid media such as the Middlebrook 7H9 has resulted in
notable improvement in rate of mycobacterial recovery from primary specimens.
Greater sensitivity is provided by use liquid media and case detection yield can be up
to 10% higher than solid media [64]. A decrease of detection time has also been
provided along with aiding the development of more efficient semi-automated and
automated commercial detection systems since the 1980s. These include radiometric
Bactec 460 TB System (BD Diagnostic Systems, MD, USA), and the non-radiometric
Mycobacterial Growth Indicator Tube (MGIT) 960 system (BD Diagnostic Systems,
MD, USA). Both systems use Middlebrook 7H9 media supplemented with a growth
supplement; oleic acid, albumin, dextrose, and catalase (OADC), and a mixture of
antimicrobial agents; polymyxin B, a mphotericin B, nalidixic acid, trimethoprim, and
azlocillin (PANTA). Notably, the MGIT 960 and other similar systems from different

suppliers, all show a higher rate of contamination than the older Bactec 460, whose
production is being discontinued. However, the latter has the major disadvantage of
radioactive waste generation [11, 58, 65]. Despite high sensitivity, throughput, and
speed, these automated systems require costly infrastructure setup, maintenance,
reliable power supply, and have a relatively large footprint, all of which are factors
hindering their routine use in low-resource settings. Liquid media offer speed and
higher mycobacterial recovery rates in cultures. However, they are more costly and
more liable to contamination, in addition to the need for stricter biosafety and staff
training measures due to risk aerosol formation [14, 17-18, 52, 58]. It is to be noted
that a contamination rate under 10% in liquid culture is regarded as acceptable [11].
Nevertheless, the overall performance advantage of culture using liquid media has
prompted WHO recommendation of their use in low and middle-income regions [3,
11]. Table 6 describes the operation principles and performance of notable
commercial culture methods

1.7.2. Molecular identification methods
One of the most common targets for bacterial identification, including mycobacteria is
the highly conserved 16S rRNA gene, and can be utilized for phylogenetic analysis.
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Sequencing of the 16S rDNA remains the reference method for mycobacterial
identification,

although

other

options

include

restriction

fragment

length

polymorphism (RFLP) analysis of amplified 16S rDNA regions or probe
hybridization. The genomic targets for such analysis are primarily in the 5’ section of
the 16S rRNA gene and amount to about 500 bp in size [66-68]. The 16S rDNA
contains 9 hypervariable regions (V1-V9) which have the sequence diversity used for
bacterial speciation [66]. V2 which spans nucleotides 137-242 was found to be useful
in detecting mycobacterial species and differentiating them [66]. Two hypervariable
regions were also recognized as particularly valuable for mycobacterial species
identification and differentiation; region A which spans positions 123 to 273, and
region B which spans positions 430 to 500. Region A is usually suitable for
identification of most mycobacteria as unique sequences are exhibited by them in that
region [67, 69-72]. A minimum of 94.3% similarity between mycobacterial species is
found in the 16S rDNA [22]. Other target genes for mycobacterial identification
include the 16S-23S internal transcribed spacer (ITS), and the genes rpoB, gyrB, and
hsp65 [11, 67-68, 72]. MTB-specific genomic regions make up about 600 kb, about
half of which have resulted from lateral gene transfer [22].
A large repertoire of molecular techniques, both commercial and in-house, is
available for MTB identification. The majority of these techniques are amplificationbased e.g. conventional and real-time PCR, strand displacement amplification (SDA),
followed by electrophoresis detection or probe hybridization. Isothermal amplification
methods like loop-mediated isothermal amplification (LAMP) are also available. To
date, no commercial molecular assay has gained FDA approval for detection of MTB
from extrapulmonary specimens. However, several have been cleared for direct
detection of MTB in processed sputum samples. Gen-Probe Amplified MTD (Genprobe Inc., USA) is FDA-approved for use with both smear-positive and smearnegative pulmonary specimens. [11, 51, 58]. Table 7 presents the main commercial
molecular detection assay for MTB detection and their target regions and performance
parameters.
A common target for in-house molecular amplification assays for MTB
identification, is the IS6110 region, however, there is notable variation in sensitivity
and specificity between different studies [51]. Notably, IS6110 RFLP has the highest
power of discrimination for strain typing and evaluation of genetic diversity, inspite
of its high technical demands [42] Although, molecular assays can shorten detection
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time to a few hours, their routine use is not always deemed practical, especially in
low-income regions. This is on account of thehigh cost of equipment set up and
maintenance, and requirement for highly trained personnel [51, 73].

1.7.3. Other detection approaches
The quest for efficient strategies detection of TB continues on all fronts and targets
various disease markers. Rotherham et al. [74] used aptamers to successfully detect a
heterodimer of the promising antigenic markers ESAT-6 and 10-kDa culture filtrate
protein (CFP-10) in TB-positive sputum samples. The detection was done using and
enzyme-linked oligonucleotide assay (ELONA). The choice of using aptamers, which
composed of single stranded DNA, is attributed to their higher specificity and lower
cost of production compared to antibodies (10-50 time cheaper) conventionally used
for antigen detection.

Baptista et al.[75] resorted to using the increasingly promising gold nanoparticles
(AuNPs), with their exquisite optophysical properties. The exquisite optical properties
of AuNPs are attributed to a phenomenon known as surface plasmon resonance (SPR)
and a closely related phenomenon called plasmon-plasmon interaction. A colloidal
solution of spherical AuNPs is red, however, when nanoparticles aggregate,
interaction of locally adjacent AuNPs (plasmon-plasmon interaction) shifts this color
to blue [75-76]. The group used nanoprobes composed of AuNPs linked to thiolmodified oligonucleotides for the detection of the DNA of MTBC members, after
first-round PCR amplification. The simple colorimetric assay is based on resistance of
AuNPs to salt-induced aggregation upon hybridization of the nanoprobes with the
complementary target due to formation of dsDNA providing charge stabilization and
steric hindrance preventing the aggregation of AuNPs. Therefore, following PCR and
nanoprobe addition, MTBC-positive samples remain red as due to hybridization of the
nanoprobes with their target, while in the negative samples the AuNPs are allowed to
aggregate and the color of the solution turns blue [75]. The same group developed the
assay further to a miniaturized platform that could be used at the “point-of-need”. The
assay was performed in a 384-well paper microplate (5 µl reaction volume per well)
thereby enhancing color visibility due the contrast with the white paper background.
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The result was documented using a smartphone camera and analyzed using a simple
RGB program anlaysis program on the same device [77].

1.8.

Guidelines for detection of active and latent TB and infections

The National Institute for Health and Clinical Excellence (NICE) in the United
Kingdom has put forth recommendations for guidance of detection efforts for TB in
2011[78]. These recommendations were based on analysis of a multitude of
systematic reviews addressing the issue of diagnosis of TB infection. For diagnosis of
active TB infection a chest x-ray is recommended as the starting point. If the x-ray
results are suggestive of TB infection, sputum smear microscopy and culture are
performed (using at least 3 sputum samples). Rapid molecular tests are recommended
for patients with positive sputum smears in case the test result would cause a
modification of patient treatment. As for latent TB detection, use of IGRAs is
recommended for individuals whose Mantoux test is positive [78].

1.9.

Detection of drug resistance

The current most commonly used detection method of active TB, sputum microscopy,
cannot detect drug resistant strains– more advanced methods are needed for DST [3,
27]. Conventional DST methods have been slow and labor-intensive due to the
lengthy time required for culturing MTB. Performance of DST is not a routine step
while testing for TB infection in most countries with high TB burden, but is typically
done in reaction to the patient’s failure to respond to standard therapy. This means
that drug resistance and DST would be performed anywhere from 2 to 8 months after
start of treatment, with no positive effect while enduring all the adverse drug effects
[24]. Conventional methods include the resistance ratio method, the absolute
concentration method, and the current gold standard proportion method. All of these
methods have rather long turn-around time (TAT), where solid media culture methods
using egg or agar-based media require 3-6weeks. This is in addition to the initial
pathogen isolation procedures which take 2-6 weeks. More recently, liquid culturebased methods have been developed which have shorter TAT (albeit still relatively
long for optimal clinical interventions), but may be significantly more expensive. This
is a crucial factor in limited-resource countries which typically have the highest TB
burden [32, 47, 79-82]. The more advanced and expensive liquid media-based
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methods shorten TAT for DST to 1-2 weeks [83]. Notably, the use of line probe
assays and automated liquid culture based DST is recommended by WHO [14].
Tables 7 and 8 summarize the main features of the phenotypic and genotypic DST
methods which will be presented in the coming sections.

1.9.1. Conventional DST methods
1.9.1.1. Phenotypic DST methods
DST testing can be performed directly on clinical specimen, or indirectly by testing
pure isolates cultured from clinical specimens. Direct testing of primary clinical
specimens saves the time needed to first culture MTB from sputum (at least 2 weeks)
and then perform the DST on the culture. Several commercial assays can be used to
perform direct DST, however, despite the time disadvantage DST is generally
performed indirectly so asto avoid the ~15% of failed tests attributed to problems and
interferences from contaminating bacteria or NTMs in the clinical samples [24, 58].
The popular proportion method remains gold standard for DST, almost 50 years after
its initial development, which can be performed using different solid media including
the most popular LJ, and Middlebrook 7H10 agar. Medium tubes with and without the
drugs to be tested are inoculated with 100 µL of the bacterial suspension are
inoculated per LJ tube with and without the drug to be tested and incubated at 37 ºC.
After 28 days of incubation the number of colonies in each tube is counted. The ratio
of number of colonies counted in the drug containing tubes compared to those in the
drug-free tubes is calculated. If the proportion exceeds 1% (for INH and RIF) or 10%
for other first line drugs, and second line drugs except para-amino-salicylic acid, the
isolate is designated resistant. In order to designate an isolate as susceptible,
incubation must be extended and on the 42 nd day if the proportion does not exceed
1%, the isolate is considered susceptible [47, 51, 84].
The absolute concentration is based on growing the strains to be tested in
presence of the drugs at critical concentrations, and the drug-susceptible reference
strain H37Rv is also grown in parallel for quality control. After 4 weeks of
incubation, if the drug-free growth control has 100 colonies while the drug-containing
culture has less than 20 colonies, the isolate is considered susceptible [24].
The resistance ratio (RR) method, involves culturing the samples and the
H37Rv strains on solid media with different drug concentrations and without the drug
as growth control. The ratio of the MIC of the patient isolated to that of H37Rv is
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calculated after 4 weeks of incubation at 37 ºC, where the MIC is defined here as the
drug concentration at which the isolate growth has less than 20 colonies. An isolate is
defined as resistant to the tested drug if its RR is 8 or more, and susceptible if it is 2 or
less. Despite being the most accurate, RR method is not the most favored on account
of its labor-intensiveness and cost. However, one advantage of the RR methods is that
it allows MIC determination. [24].
On the commercial front, several systems are already available and used for
MTB detection, which provide the facility for high throughput DST of MTB. The
MGIT 960 system is the only one recommended by the WHO for surveillance of drug
resistance (first-line drugs) [84], and none of the commercial systems is FDAapproved for second-line drugs [58]. The automated step in the MGIT 960 is the
reading of the tubes, while all other preparatory steps are manual. Consequently, the
main advantage is the reduction in turnaround time to a few days, the overall
workload is not significantly less than the regular manual method. However, the
reading throughput is substantially higher [47, 84]. Characteristics of notable
commercial phenotypic DST systems are presented in table 5.

1.9.1.2. Genotypic DST methods
Many of the commercial molecular MTB detection systems are also suited, or
versions of them for resistance detection (table 7), and for in-house assays, similar
principles are utilized for resistance detection. Commonly, utilized strategies include
probe hybridization, real-time PCR with hybridization probes, while DNA sequencing
remains the reference standard. Genotypic methods offer the tremendous advantage of
bringing down the time for DST to 1-2 days instead of weeks. However, this comes at
a high monetary cost and with practical reservations [51, 55]. A major issue is the fact
that the data on resistance–inducing mutations are incomprehensive, and not all
mutations are translated into phenotypic resistance. Moreover, molecular methods do
not reflect the proportion of the resistant bacteria in the sample [55]. Additionally, the
likelihood of false negative results is not to be ignored. This is because absence of a
mutation does not necessarily mean the isolate is phenotypically susceptible to the
drug. It is not an uncommon finding that isolates demonstrate phenotypic drugresistance while molecular testing shows they lack known resistance-conferring
mutations [49].
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Initially developed over 15 years ago, line probe assays (LPAs) utilize PCR
amplification with labeled primers, followed by solid phase reverse hybridization. The
labeled PCR amplicon is incubated in solution on nitrocellulose or nylon membranes
strips on which target-specific probes are immobilized in parallel lines on solid
support. Unbound DNA is then washed off, the hybridized probes are visualized by
color development through enzymatic reaction utilizing the labeled amplicon,
revealing a pattern of probe hybridization which reflects the resistance status [84-86].
There are currently three LPAs on the market; GenoType® MTBDR/MTBDRplus
and Geno-Type® MTBDRsl (Hain Lifescience, Nehren, Germany) and INNO-LiPA
Rif.TB (Innogenetics, Zwijndrecht, Belgium) [11, 55].
One of the main issues with use of molecular assays is the high risk of large
scale cross contamination, which is why fully automated closed systems are preferred
despite cost. Additionally, since PCR amplification is an initial step in many
genotypic assays, presence of polymerase inhibitors is a potential problem [55, 84].
However, this was addressed in another successful test which is a hemi-nested realtime PCR based assay for RIF DST Xpert MTB/RIF (Cepheid Inc., CA, USA) which
has the advantage of automation and being a closed system, thereby minimizing risk
of cross contamination. The combination of speed and specificity of LPAs and Xpert
MTB/RIF assays have led to the WHO recommendation for the expansion for their
use in screening for drug resistance and initiation of measures to lower cost for
accessibility by impoverished areas with high burden TB [3, 55, 58, 87]. Both INNOLiPA RifTB and Xpert MTB/RIF can detect extrapulmonary TB with high specificity
(pooled specificity 94% and 96%, respectively), but with limited sensitivity (pooled
sensitivity 68% and 63%, respectively) [55].

1.9.2. Emerging DST methods
About 60% of the global number of TB patients present in remote and peripheral
healthcare centers lacking the resources and infrastructure for advanced and molecular
diagnostic systems [88] . Consequently, a number of new techniques have emerged to
circumvent the disadvantages of high cost and long TAT of conventional culture
DST, some of which have already gained WHO endorsement. Other promising
approaches are yet to accumulate a sufficient body of supporting evidence e.g.
mycobacteriophage-based assays, others. The latter include the microscopic
18

observation drug susceptibility (MODS) assay, and the colorimetric assays; the nitrate
reductase assay (NRA) and the colorimetric redox indicator (CRI) method [32, 84,
89].

1.9.2.1. Microcolony growth examination methods
1.9.2.1.1. Microscopic observation drug susceptibility assay (MODS)
The proof-of-concept of MODS as a rapid liquid culture-based method for
simultaneous detection and DST directly from decontaminated sputum was first
provided by Caviedes et al. [90], and illustrated the validity of direct detection of
resistance to RIF and INH with sensitivity of 92% and specificity of 93%.
Processed sputum samples (or isolate bacterial suspensions) are inoculated
into supplemented Middlebrook 7H9 broth with and without drugs (INH and RIF) at
critical concentrations (0.4 and 1 µg/mL, respectively), in 24-well microtiter plates
(figure 9). The plates are sealed in zip-lock bags and incubated for 7 days at 37 ºC.
The plates are then microscopically examined for the characteristic cording pattern of
MTB organisms (figure 10). If no characteristic MTB cords are detected in the drugfree wells, the reading is repeated every other day up to 21 days, after which the
sample is declared negative [91-92]. The most recent meta-analysis found MODS to
have pooled sensitivities of 88.6% and 96.8% for detection of INH and RIF
resistance, respectively, in direct specimens (n=7), and pooled specificities of 98.5%
and 99%, with an average TAT of 11.6 days. As for indirect testing the pooled
sensitivities were 93% and 100% for INH and RIFresistance detection, respectively,
and the pooled specificities were 100% for both drugs, with an average TAT of 6.5
days (n=2) [89].
The main advantage of MODS is that it utilizes common facilitiesavailable in
TB laboratories, including those with limited resources, with which the personnel are
typically familiar. Also, direct DST testing can simply be performed in biosafety level
2 laboratories and the costly sophisticated level 3 set up is uncalled for. MODS
combines the relatively rapid growth of culture in liquid media, with a much more
cost-effective methodology. However, this test method is still fairly labor intensive
and technically demanding, particularly in inoculation, where contamination risk is
greatest [32, 47, 49, 82, 84]. Average contamination rate in MODS studies was found
to be 7.4% [89]. Caution must be exercised when using MODS for direct testing in
regions with high NTM prevalence as the evidence is still lacking with respect to the
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assays ability to differentiate them from MTB, particularly M. chelonae. One
proposed solution for this issue is the inclusion of PNB-containing well which would
specifically inhibit MTB growth [84, 89].

1.9.2.1.2. Thin Layer Agar (TLA) Method
The thin layer agar (TLA) method is also known the microcolony method, and can
detect mycobacterial growth on agar media within about 10 days. This method uses
quadrant agar plates with drug-free and drug-containing quadrants (at critical
concentrations). The quadrants are inoculated with the processed sputum and
incubated at 37 ºC with 5% CO2. The plate is then examined with a light microscope
with 100x magnification for colony growth [84, 93-94]. One version of TLA includes
PNB in one of the quadrants to ensure growth is MTB complex and not an NTM [94].
The current body of evidence available for TLA remains insufficient for endorsement
of its worldwide use [55], where a recent meta-analysis identified only 3 assessment
studies of TLA, all showing 100% concordance with the reference proportion method.
Also, a thorough cost analysis is not yet available [89].

1.9.2.2. Colorimetric methods
1.9.2.2.1. Colorimetric Redox Indicator (CRI) Assay
The CRI assay detects the metabolic activity of viable mycobacteria that reduce a
redox indicator added to the medium after the isolates are incubated with each test
drug. The reduction causes a change in the color of the indicator, which varies based
on the used indicator (e.g. Alamar blue or resazurin changes from blue to pink; 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) changes from yellow
to violet). The metabolic reactions of the viable mycobacteria reduce resazurin (blue)
to resorufin (pink), while in case of MTT (yellow), it is reduced to insoluble formazan
(violet), which is then solubilized prior to result reading [79, 95].
The assay is performed in a microtiter plate, where the isolates to be tested are
incubated for 7 days at 37ºC with a serial dilution of the drugs in broth, and growth
and sterility controls are also included. Then the redox indicator is added, the plate
reincubated, and the plate read the following day (figure 11) [73, 96].
The CRI assay was initially developed for screening and evaluation of antituberculosis drugs and utilized the propriety redox indicator Alamar blue [97] and the
microplate format was introduced by Franzblau et al. in 1998 [98]. It was later
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established that Alamar blue and resazurin are basically the same active compound
(figure 12) and undergo the same reaction in the CRI assay. However, unlike Alamar
blue, resazurin, usually supplied as a sodium salt, is a non-proprietary reagent [97].
Different studies investigated the performance of the CRI assay using MTT,
Alamar blue, or resazurin, and found them to yield comparable results [79], however,
there are some factors to be considered in the indicator choice, including reagent
propriety which affect both cost and access to reagent. As for MTT, the main issue
associated with its use is the need for an additional solubilization step for
theformazan, which requires the plate to be opened one more time, thus posing an
additional risk of assay contamination and biosafety hazard due to possible aerosol
formation [97]. Moreover, there is a risk of false-resistance results with INH due to its
potential interference with formazan formation [99].
The Alamar blue and resazurin CRI has demonstrated reliable and consistent
results with regards to INH and RIF susceptibility testing, and subsequently for MDRTB detection. However, some discrepancies with regards to MICs were found when
testing ETH and SM, but had little impact on final designation of sample as resistant
or susceptible. The assay can also be carried out using an inoculum from both solid
and liquid cultures, with no adverse effect on performance [100]. The resazurin-based
CRI for MDR-TB detection was first introduced by Palomino et al. [96], which is
now WHO-endorsed and a standardized protocol is now available [64, 101]. An
evaluation study of the assay in Madagascar yielded sensitivity of 95% for both INH
and RIF resistance detection, while the specificity was 97.3% for INH and 100% for
RIF. The total TAT for CRI, including initial isolation was 4-5 weeks versus 7-10
weeks for LJ-based proportion method [102]. Overall, the reported TATs for these
assays are much shorter than the 3-6 weeks needed for conventional methods, the
TATs range between 7-14 days for CRI, exclusive of initial isolation [79].
Moreover, a study by Martin et al. [103] incorporated nicotinamide in a
modified CRI to perform DST for the typically problematic pyrzinamide, on account
of its requirement for low pH in the media. Additionally, CRI is being evaluated for
detection of XDR-TB by testing second-line drugs and fluoroquinolones [97, 104].
Despite low expectations of success due to high contamination chances, use of direct
CRI testing on sputum has been attempted using MTT, with promising results, but
evidence remains too scarce for constructive evaluation [73, 97, 105].
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1.8.2.2.2

Nitrate reductase assay (NRA)

Similar to CRI, the NRA utilizes the biochemical activity of viable Mycobacteria in
the sample. The basis of NRA is the fact that MTB can reduce nitrate to nitrite, which
is one of the distinctive biochemical properties of MTB among mycobacteria. This
ability is lacked by M. bovis, another MTBC member. In this assay the sample is
incubated with and without the test drug in liquid media containing potassium or
sodium nitrate at 1000 µg/mL concentration. Resistant strains will remain viable in
the presence of the drugs, convert the nitrate in the medium to nitrite and result in the
change of the indicator Griess reagent color to pink. Griess reagent contains an azo
dye that changes color upon reaction with nitrite in the medium (figure 13).It is
composed of 50% (v/v) hydrochloric acid, sulfanilamide 0.2% w/v, and N-(1naphtyl)ethylene-diamine dihydrochloride 0.1% (w/v) mixed in ratio of 1:2:2. [81,
106-107].
NRA can be performed using either solid or liquid media [32, 47, 81, 108],
and the solid media-based format has been endorsed by the WHO for both direct and
indirect DST [64]. Direct NRA was found to yield results in median time of 10 days
(range 10-23 days), and detected MDR-TB with a sensitivity of 97% and specificity
98% [107]. The indirect LJ-based NRA does not provide significant TAT advantage
over conventional methods based on use of solid media [47].
A few reports illustrate the use of NRA based on liquid media with good
performance [99, 108-110]. In one approach, the assay was performed using 7H9
broth with and without INH and RIF at critical concentrations, in screw-cap tubes to
minimize risk of aerosol formation while benefiting from the high mycobacterial
recovery rate of liquid media. Despite providing more safety, the use of the liquidbased NRA in tubes is rather cumbersome and impractical in terms of throughput,
particularly if MIC determination is to be carried out. Kumar et al. reported the use of
liquid-based NRA in 96-well microtiter plates [110-111]. Despite safety concerns, this
format allows handling of smaller culture volumes while allowing for MIC
determination and increasing throughput as multiple samples can be tested in the same
plate with multiple drugs. The microplate assay showed 96% concordance with the
proportion method for detection of INH resistance and 100% for RIF, with results
available within 8 days [110].
By detecting the nitrate reduction activity of MTB prior to colony formation,
NRA offers sensitivity and speed. However, a potential limitation albeit minor, is the
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assay’s inability to detect the rare nitrate reductase-negative strains of MTB.
Although, these represent less than 1% of strains, this caveat must always be taken
into consideration [112]. Another point which must also be considered in use of NRA
is that Griess reagent cannot detect the reduction of nitrate, beyond nitrite, to nitric
oxide. The issue is mitigated by addition of a small amount of zinc dust to negative
tubes, if the nitrate in the medium has already been reduced beyond nitrite, the color
will not change and the result will be considered a positive. However, if the color
changes to pink due to rapid reduction of nitrate by zinc, this means it was a true
negative in the beginning and no nitrate reduction was undertaken by mycobacteria
[112-113]. The analysis by Martin et al. [81] reported overall TATs of 5 to 12 days
for indirect NRA, and 14 to 18 days for direct NRA. Direct testing of sputum using
NRA on liquid media is promising but current data is insufficient for proper
evaluation [81].

1.9.2.3. Mycobacteriophage-based assays
Another promising strategy that is yet to accumulate enough evidence to warrant
recommendation of large scale or routine use is the mycobacteriophage assay. This
assay utilizes the natural specificity of certain phage types for infection and
replication within mycobacteria [24, 55, 65, 84].
There are two approaches utilizing mycobacteriophage which were used for
development of drug resistance detection assays, and a single commercial provider;
Biotec Labs Ltd, Ipswich, UK. In the first approach, the basis of detection is phage
amplification, and is the basis of the only commercial phage-based MTB resistance
detection assay; the CE-marked FASTPlaque assay (Biotec Labs Ltd, Ipswich, UK).
D29 lytic phage is incubated with the decontaminated sputum samples, with and
without RIF, and then a virucidal agent is added to eliminate excess phage outside of
the mycobacterial cells. Progeny phage generation in the viable MTB cells result in
plaque formation on a lawn of

M. smegmatis (non-pathogenic fast-growing

mycobacterium) on agar plates, and RIF resistance can thus be detected within 2 days
[65, 84, 114]. According to the most recent meta-analysis, an average of 21% of direct
sputum tests using this strategy yielded uninterpretable results. The manufacturer
introduced the use of an antibiotic supplement containing nystatin, oxacillin and
aztreonam (NOA). This reduced bacterial and fungal contamination by 68% but
increased the assay cost. the pooled sensitivity of the direct commercial phage
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amplification assay was 93.6%, and 95.7% for the indirect assay, and the pooled
specificities were 96.3% and 94.1%, respectively [114].. The direct assays were
shown to suffer from unexplained false-resistance results as well as contamination
problems [84, 114], where.
The other approach, the luciferase reporter phage assay, is based on using
bioengineered phages incorporating a luciferase gene, and is used on isolates. These
phages are incubated with the sample, with and without the drug, and the medium
contains the substrate luciferin. In viable mycobacteria, the engineered phage is able
to produce a light signal in presence of luciferin and cellular adenosine triphosphate,
which can be detected using a luminometer, and a result is obtained within 2 days [65,
84]. Commercialization of this assay was attempted by Sequella Inc., USA into a
complete system termed Bronx Box. However, these attempts were recently
abandoned. The mycobacteriophage assays have demonstrated the advantages of
rapidity and high sensitivity; however, their drawbacks hinder their practical
application. At the heart of thesassays are substantial cost elements such as that of the
engineered phage, the NOA supplement, and the need for a luminometer for signal
detection (in case of the luciferase assay). Moreover, the time-saving capability of
direct sputum testing is hindered by siginifcant rates uninterpretable results, and when
this is combined with the cost factor, the actual practicality of such assays remains
questionable [30, 114].
The above mentioned assays are appropriate examples of approaches that are
principally sound, but are tackled by the practical and logistical challenges of TB
detection and resistance testing, including the nature of the primary specimens, and
slow growing nature of MTB. This is the elusive nature of the balance between
efficient analytical performance and turnaround time, and cost effectiveness and
practicality, bearing in mind the financial and logistical settings of the areas and
markets where TB DST assays are most needed.
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2. Project Aims
1. Evaluation of the performance of the colorimetric redox indicator (CRI) and the
nitrate reducate assay (NRA) methods for detection of multidrug resistant
tuberculosis (MDR-TB), defined by resistance to both isoniazid (INH) and
rifampicin (RIF), in limited resource settings with adequate performance. The
performance is compared with microscopic observation drug susceptibility assay
(MODS) and the commercial MGIT 960.

2. PCR amplification and DNA sequencing of part of the 16S rDNA from ten
random clinical samples being tested using CRI & NRA. This is to confirm that
the samples’ identities as Mycobacterium tuberculosis (MTB), and to determine if
there are any strain variations among these Egyptian clinical samples.
3. PCR amplification and DNA sequencing of gene segments containing common
resistance-conferring mutations, for selected samples. This is to gain insight
regarding the molecular basis of the detected phenotypic resistance of the samples.
The target genes are katG and inhA for INH resistance, and rpoB for RIF
resistance.
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3. Materials and Methods
3.1. Samples
Thirty four mycobacterial isolates on LJ medium, from the sample archive of the
Naval Medical Research Unit 3 (NAMRU-3) were tested in this study. The samples
were isolated from sputum samples, collected between 2009 and 2011, from Egyptian
patients diagnosed with TB, processed using NALC-NaOH method.The samples were
collected through research project NAMRU3.2010.004: Integration of Microscopic
Observation Drug Susceptibility (MODS) assay technology into tuberculosis
surveillance in Egypt between 2009 and 2011, from patients diagnosed with TB. The
reference strain H37Rv (pathogenic, but sensitive to INH and RIF) was also included.
The available samples contain 9 drug-resistant isolates, resistant to INH and/or RIF.
Five isolates were resistant to both RIF and INH and are thus considered as MDR, 3
isolates were INH-monoresistant, and 1 was RIF-monoresistant.

3.2. Media Preparation
3.2.1. MODS
7H9 broth was prepared by weighing 5.9 g Middlebrook broth base powder (BD, NJ,
USA cat. # 271310), 1.25 g casitone (BD, NJ, USA cat.# 225930) and dissolved in
900 mL of distilled water, along with 3.1 mL glycerol. The broth was then autoclaved
and incubated for 24 h at 37°C and checked for sterility (indicated by lack of turbidity
after incubation).

3.2.2. CRI and NRA
7H9-supplemented (7H9-S) broth consisting of Middlebrook 7H9 broth, 10% OADC
supplement (oleic acid, albumin, dextrose, catalase) (BD, USA, cat. #211886), 0.5 %
glycerol, and 0.1 % casitone was prepared as follows. 0.94 g of 7H9 powder were
weighed and dissolved in 180 mL of distilled water, then 0.2 g of casitone were added
and dissolved. This was followed by addition of 1 mL of glycerol, and the broth was
autoclaved. After autoclaving and cooling, 20 mL of OADC were added and mixed
well. For use in NRA, 1 mL of filter-sterilized NaNO3 (Sigma- Aldrich, cat. # S50221KG) (20% w/v) was added to make 7H9-SN broth. Both media were then incubated
for 24 h at 37 °C and checked for sterility.
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3.3. Preparation of Drug Solutions
3.3.1. MODS
An INH stock of 8 mg/mL was prepared by dissolving 20 mg INH powder (SigmaAldrich, cat. # 377-50G) in 2.5 mL distilled water. A RIF stock was of 8mg/mL was
prepared by dissolving 20 mg RIF powder (Sigma-Aldrich, cat. # R3501-5G) in 1.25
mL dimethyl sulfoxide (DMSO) and then adding 1.25 mL distilled water. Both
solutions were filtered using 0.2 µm syringe filters (CHM, Spain, cat.# BM316) and
aliquoted and stored at -20ºC.

3.3.2. CRI and NRA
An INH stock of 1 mg/mL was prepared by dissolving 2 mg INH powder in 2 mL
distilled water. A RIF stock of 10 mg/mL was prepared by dissolving 20 mg RIF
powder in 2 mL absolute methanol. Both solutions were filtered using syringe filters
and aliquoted and stored at -20ºC.

3.4. Testing of Samples Using MGIT 960 System
All samples were tested using BACTEC MGIT 960 (BD, NJ, USA), according to
manufacturer protocol.

3.5. MODS Testing
The assay was performed as previously described in [91]. 4.5 mL of the prepared 7H9
broth were placed in sterile screw-cap tubes, and 0.5 mL OADC were added to each
tube. Several mycobacterial colonies were harvested from LJ slants into sterile screwcapped tube containing 100 µL of freshly prepared sterile 0.04% Tween 80 (BD, NJ,
USA, cat # 231181) solution and 4-5 sterile glass beads. The tubes were vortexed for
2-3 minutes, then allowed to stand for 5 minutes. 3 mL of the Tween 80 solution were
then added and vortexed again for 20 seconds and the tubes were allowed to stand for
30 minutes. The supernatant was transferred to another sterile tube and the
suspension’s turbidity was adjusted to 1.0 McFarland, and 5 µL of each bacterial
suspension was then added to each supplemented media tube to make up the final
inoculum. Stock INH and RIF solutions were diluted in broth to working
concentrations of 4 µg/mL and 10 µg/mL, respectively. 100 µL of the supplemented
broth were placed in the first two wells of each column of a sterile 24-well microplate
(BD ,NJ, USA, cat.# 353047), to act as drug-free controls, and 100 µL of each of the
27

working drug solutions were placed in the other two wells 900 µL of the inoculum
were placed in each of the respective wells of the microplate for each sample. One
column included only 1 mL broth in all well, with no inoculum to serve as a negative
control. The plates were then covered with their lids, sealed with autoclave tape,
placed in ziplock bags, and incubated at 37°C. After incubation for 5 days, the plates
were then examined under inverted light microscope with 40x magnification (after
visual examination of wells for turbidity to rule out contamination) to observe the
characteristic cording pattern of MTB (figure 10). If no cords the plate was
reincubated and examined again at 7 days, or every two days up to 21 days.

3.6. CRI Testing
The assay was performed according to the protocol by Martin and Palomino [101].
100 µL of 7H9-S broth were placed in each well of a 96-well microplate (Greiner Bio
One, cat. # 655061), excluding outer perimeter wells. The drug stock solutions were
diluted in 7H9-S broth to prepare a working INH solution with a 4 µg/mL
concentration and a RIF solution with an 8 µg/mL concentration. 100 µL of each drug
working solution were placed in the first row of columns 2-9, then 2-fold serial
dilutions of the drugs were made down the columns. Inoculums from 21 -28 day old
isolates from LJ cultures were prepared in 7H9-S broth and adjusted to 1.0 McFarland
standard. The inoculum was diluted 1:20 using 7H9-S broth, and 100 µL of the
diluted inoculum were used to inoculate the plate (figure 14). Growth control wells
without drugs for each sample were included as well as sterility control wells with
only 7H9-S broth, and outer perimeter wells were filled with sterile distilled water.
The plate was placed in ziplock bag and incubated for 7 days at 37ºC then 30 µL of
0.01% resazurin solution in distilled water were added to each well and the plate
sealed and reincubated overnight then read.

3.7. NRA Testing
The assay was performed based on the method of Kumar et al. [110] with
modifications. 50 µL of 7H9-SN broth were placed in all wells of a sterile, flatbottom 96-well microtiter plate, except column 1 and 12. The drug stock solutions
were diluted in 7H9-S broth to prepare a working solution of INH (16 µg/mL) and a
working solution of RIF (32 µg/mL). 50 µL of each working drug solution were
placed in the first row of columns 2-9, then 2-fold serial dilutions of the drugs were
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made down the columns. Inoculums from 10-21 day old isolates from LJ cultures
were prepared in 0.05% Tween 80 in 7H9-S broth and adjusted to 1.0 McFarland
standard. The inoculum was diluted1:10 in 7H9-SN and the plate was inoculated with
50 µL of the diluted inoculum in each well (figure 15). Growth control wells without
drugs for each sample were included as well as sterility control wells with only 7H9 SN broth and no inoculum. The plate was placed in ziplock bag and incubated for 7
days at 37ºC then 50 µL of Griess reagent (Sigma-Aldrich, cat. # 03553-100ML) were
added to each well and the plate sealed and read.

3.8. DNA Extraction
Extraction

of mycobacterial DNA was performed using a modified enzymatic

method [115]. The sealed LJ slant tubes containing the bacterial growth were first
heated in an 80ºC water bath for 1 hr. The bacterial cells were then harvested in 2 mL
Tris-EDTA (TE) buffer, pH=8, then frozen for 4 hrs, to weaken the cell wall. The
pellet was then thawed and resuspended in the TE buffer. Delipidation to aid cell
lysis, was then performed by adding an equal volume of chloroform/methanol mixture
(2:1) and rocking the tubes for 2 minutes. The suspension was then centrifuged at
5000 g for 20 minutes, and the bacteria formed a tight band at the interface of the
aqueous and organic layers, which were discarded and the bacterial band retained.
The tube containing the bacterial band was heated with the cap opened at 55ºC for 10
minutes to remove any traces of chloroform, and then the bacterial band was
resuspeneded in 2 mL TE buffer. 200 µL of Tris-HCl, pH = 9, were then added,
followed by 10 µL of lysozyme, stock concentration was 10 mg/mL. The tubes were
then incubated overnight at 37ºC, and then 10 µL of DNAse-free RNAse (Promega,
cat # M6101), stock concentration 10 mg/mL, were added, and the tubes reincubated
at 37ºC for 30 minutes. Then a DNA extraction kit (Qiagen, USA, cat.#51304 ) was
used in accordance with the protocol for gram-positive bacteria after the lysozyme
digestion step.

3.9. Quantification of extracted MTB DNA
Concentration of extracted DNA was determined by spectrophotometric measurement
at 260 and 280 nm using NanoDrop spectrophotometer (Thermo Scientific, USA).

3.10. Sequencing of 16S rDNA
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3.10.1. Primer design
A pair of primers targeting a conserved part of the 16S rDNA of Mycobacterium
genus was designed Vector NTI Advance® v.11.5 (Invitrogen). The conserved region
was chosen based on multiple sequence alignment analysis against Mycobacterium
genomes sequences published in NCBI Gene Bank using the same software package.

3.10.2. PCR amplification of 16S rDNA region
A 514 bp region of the 16S rDNA gene was amplified using standard PCR using our
designed primers, for 10 randomly chosen isolates from the initial 34 isoaltes . First,
the extracted MTB DNA was digested using BamHI restriction enzyme (Promega),
according to manufacturer protocol.

BamHI was selected due to absence of a

restriction site within the target region. Dimethylsulfoxide (Sigma-Aldrich,
cat.#276855) was added in the master mix (Promega, USA, cat.#M7142), at 5% final
concentration, and the mix was used for PCR. A 50 µL PCR reaction was prepared by
mixing 25 µL PCR Master Mix 2X, 2.5 µLof 10 µM of each of the forward and
reverse primers, 5 µL of DNA template, and 15 µL nuclease-free water. PCR was
done in 25 cycles: initial denaturation at 95°C for 2 min, denaturation at 95°C for 30
s, annealing at 61°C for 1 min, extension at 72°C for 45 s, and final extension at 72°C
for 2 min in a thermal cycler (Veriti, Applied Biosystems CA, USA). Amplification
was verified by electrophoresis of the amplicon on 2% agarose gel and visualization
of the ~500 bp band using ethidium bromide staining. A 100 bp ladder (Promega,
USA, cat.#G2101) was used for band size comparison.

3.10.3. DNA sequencing of 16S rDNA
The same primers that were used for PCR amplification of the 16S rDNA region were
used for sequencing (forward and reverse) the amplicon using ABI 3730xl DNA
sequencer (Applied Biosystems, CA, USA) according to manufacturer’s protocols.

3.10.4. 16S DNA sequence data analysis
Vector NTI 11.5 software was used to assemble, trim, and then align all sequencing
results along with the full 16S sequence of the reference strains H37Rv (GenBank no.
X52917.1), and they were also analyzed using NCBI Blast for alignment against
available DNA sequences in the NCBI database.
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3.11. Sequencing of INH and RIF resistance-related genes
3.11.1. Primer design
Two pairs of primers were obtained from the literature to target katG [116] , and rpoB
[117] genes, while another pair targeting inhA regulatory region was designed using
the Vector NTI 11.5 software (table 9).

3.11.2. PCR amplification of resistance-related regions of katG, inhA, and rpoB
The target regions of katG, rpoB, and the regulatory region of inhA of 3
phenotypically drug resistant samples, 3 phenotypically susceptible samples, and the
reference drug-susceptible strains H37Ra, were amplified by conventional PCR. First,
the extracted MTB DNA was digested using EcoRI restriction enzyme (Promega,
USA, cat# R4014), according to manufacturer protocol. EcoRI was selected due to
absence of a restriction site within the target region. Dimethylsulfoxide
(DMSO),(Sigma-Aldrich, cat. #276855) was added in the master mix (Promega,
USA, cat.# M7142), to yield final concentration of 5%, and the mix was then used for
PCR. A 50 µL PCR reaction was prepared by mixing 25 µL PCR Master Mix 2X, 2.5
µL of 10 µM of each of the forward and reverse primers, 5 µL of DNA template, and
15 µL nuclease-free water. PCR was done in 25 cycles: initial denaturation at 95°C
for 2 min, denaturation at 95°C for 30 s, annealing for 1 min (temperature used for
each primer is listed in table 9), extension at 72°C for 45 s, and final extension at
72°C for 2 min in a thermal cycler (Veriti, Applied Biosystems CA, USA).
Amplification was verified by electrophoresis of the amplicon on 2% agarose gel and
visualization of the bands using ethidium bromide with comparison to a 100 bp ladder
(Promega, USA, cat.#G2101).

3.11.3. DNA sequencing of katG, inhA, and rpoB
The same primers that were used for PCR amplification of the inhA, katG and rpoB
regions were used for sequencing (forward and reverse) the amplicon using ABI
3730xl DNA sequencer (Applied Biosystems, CA, USA) according to manufacturer
protocols.

3.11.4. DNA sequence data analysis for katG, inhA, and rpoB
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Vector NTI 11.5 software package was used to assemble, trim, and then align all
sequencing results along with the full sequence of the reference strain H37Ra, and
they were also analyzed using NCBI Blast.

3.12. Biosafety measures
All steps for preparation of MODS, CRI, and NRA were performed in a level 2
biosafety cabinet (BSC-2), with the operator wearing N-95 mask. For plate reading
and documentation, the plates were always maintained in the sealed ziplock bags, and
the N-95 mask was always on when the plates were removed from the BSC to be
examined under the microscope (in case of MODS) or examined using the plate
mirror and photographed. As for the DNA extraction process, the heat
decontamination, and harvesting the cells into the TE lysis buffer steps are performed
inside the BSC while wearing the N-95 mask. The remaining steps were performed
outside the BSC with common level 2 laboratory safety precautions.
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4. Results
4.1. Samples
Thirty four mycobacterial isolates, comprising the sample pool were characterized
using both MODS and MGIT, with complete concordance between both methods
(table 10). Five samples were found to be MDR, 3 monoresistant to INH, 1
monoresistant to RIF, and 25 were sensitive to both drugs. The MGIT testing was
performed on the standard panel of first-line drugs SM, INH, RIF, ETH (SIRE panel).
6 isolates also demonstrated resistance to SM and 2 to ETH. One sample was only
included in the molecular studies and not in the culture-based resistance detection
using CRI and NRA, for safety reasons, as MGIT results indicated its resistance to all
4 drugs in the SIRE panel.

4.2. Phenotypic detection of drug resistance
4.2.1. Colorimetric redox indicator assay (CRI)
CRI assay was performed on 31 isolates; 4 isolates were MDR, 3 monoresistant to
INH, 1 monoresistant to RIF, 23 sensitive to both drugs. The MICs of the resistant
isolates ranged from 0.125 to > 1 µg/mL for INH, and from 0.5 to >2 µg/mL for RIF,
and thus one isolate which was INH monoresistant by MGIT and MODS was found
sensitive by CRI. Concordance was 96.7% with MGIT and MODS reference methods,
and assay reproducibility was established by random repeat testing of isolates.
Performance of CRI is presented in table 11. An example of a CRI plate result is
shown in figure 16.

4.2.2. Nitrate reductase assay (NRA)
NRA was performed on 30 isolates, 4 MDR, 3 monoresistant to INH, 1 monoresistant
to RIF, and 22 sensitive to both drugs. The MICs of the resistant isolates were
determined, The MICs of the resistant isolates ranged from 5 to > 8 µg/mL for INH,
and from 10 to >16 µg/mL for RIF. Concordance was 93.3% with MGIT and MODS,
and false resistance to RIF was obtained for one INH monoresistant isolate, and
another INH resistant isolate yielded a false sensitive result for INH. Assay
reproducibility was demonstrated by random repeat testing of isolates. Performance of
NRA is presented in table 12. An example of an NRA plate result is shown in figure
17.
33

4.2.3. Turnaround times (TAT)
CRI median TAT was 8 days (range 7 to 10 days), and that of NRA was 7 days (range
6 to 8 days). MGIT TAT ranged from 5 to 13 days, and MODS from 7 to 21 days.

4.2.4. Age of tested isolates in CRI and NRA
Since both CRI and NRA are indirect testing methods, that require initial bacterial
isolation, the age of isolates affected the TAT. Optimum age of isolates testing was
determined to be 18-29 days for CRI, and 13-21 days for NRA, which yielded clearest
and most consistent results. Although, valid CRI result were obtained for isolates
ranging in age from 12-32 days, and 12-28 days for NRA (one MDR isolate 32 days
old yielded valid results).

4.2.5. Cost analysis
The cost of both assays was estimated with respect to used media, drugs, indicator,
and microplates and other consumables. The cost of testing an isolate for resistance to
both INH and RIF using CRI and NRA was found to be $4.5 and $5.2, respectively.

4.3. PCR amplification and sequencing of 16S rDNA
4.3.1. Selection of PCR primers
The target region for the designed primers was chosen to be a highly conserved part
of the 16S rDNA of Mycobacterium genus, as multiple alignment analysis against
Mycobacterium genomes sequences, including the reference strain H37Rv published
in NCBI Gene Bank showed high degrees of homology (figure 18).

4.3.2.

PCR amplification of 16S rDNA region

A clear band of ~500 bp size was visualized on agarose gel electrophoresis thus
supporting amplification of the target region (figure 19).

4.3.3. DNA sequencing
The PCR amplicons for the 16S rDNA were sequenced and the sequencing results
showed clear sharp bands and low background noise (figure 20).
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4.3.4. Blast analysis
Blast analysis of sequencing results for 16S rDNA (forward and reverse sequences
assembled) using NCBI nucleotide Blast software yielded results supporting sample
identities as Mycobacterium tuberculosis (figure 21). E-value was 0.0 indicating the
high significance of the obtained results. Alignment of the sequences and construction
of the relationship dendrogram showed that all the samples clustered closely except
for two samples (#321 and #361), which clustered together differently (figures 22 and
23).

4.3.5. Mutation analysis
The amplified part of 16S rDNA encompasses the rrs gene, which is known to harbor
point mutations correlated with resistance to SM. The sample sequences and that of
the reference H37Rv (GenBank no. X52917.1) were aligned using AlignX Vector
NTI 11.5. Analysis of the sequences’ alignment for polymorphisms showed two point
mutations at nucleotide 513 (AT) and 526 (CT) based on E. coli numbering
system, in two samples known to be SM-resistance by MGIT analysis (figure 24).

4.4. PCR amplification and sequencing of inhA, katG and rpoB regions
4.4.1. Selection of PCR primers
All primers for katG, inhA, and rpoB were verified for specificity by multiple
alignment analysis against Mycobacterium genomes sequences published in NCBI
Gene Bank using the Vector NTI 11.5 software package.

4.4.2.

PCR amplification of inhA, katG and rpoB regions

A clear band of ~400 bp size for katG amplicon, and at ~600 bp size for inhA and
rpoB amplicons were visualized using agarose gel electrophoresis thus supporting
amplification of the target regions.

4.4.3. DNA sequencing
The PCR amplicons for the inhA, katG and rpoB genes were sequenced and the
sequencing results showed clear sharp peaks and low background noise.
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4.4.4. Mutation analysis
The katG sequences obtained from the isolates, and the sequence of the reference
strain and that of the full gene for the reference H37Ra (GenBank accession # NC_

009525) were aligned using AlignX Vector NTI 11.5. The process was repeated with
the rpoB sequences. Analysis of the sequences’ alignment for polymorphisms showed
a point mutations in the katG sequences of samples #314 and #344, both MDR, in
codon 315. As for rpoB, a point mutation in codon 526 in sample #344 (MDR), and
another mutation in codon 531 in sample #314, which is also MDR. No mutations
were found in the inhA regulatory region. The observed mutations and corresponding
amino acid changes are listed in table 13. Figures 25 and 26 present the sequence
alignments showing the described mutations.

36

5. Discussion
5.1. Evaluation of colorimetric DST assays CRI and NRA
The regular challenge facing DST for MTB infection is striking the balance between
cost and speed while maintaining accuracy. The most rapid direct molecular methods
are very costly and require high expertise, and even the slower automated culture
systems are also expensive with high infrastructure and maintenance requirements.
The more affordable conventional culture methods have a very long TAT, this is on
top of the specific technical challenges of each individual assay. The aim of this study
was to evaluate the performance of two colorimetric liquid culture-based assays that
could fit the requirements for TB DST in the regions where resources are limited, and
especially where MDR-TB is a particular issue.
A selection of 34 mycobacterial isolates grown on LJ media from processed
sputum obtained from Egyptian TB patients, was characterized using for growth and
DST using the in-house method MODS and the commercial liquid culture system
MGIT 960. Both MODS and CRI are in-house methods endorsed by the WHO for
DST, while the microplate format used in this study has not been sufficiently
investigated.
The primary point of strength in MODS is its suitability for use for direct
sputum testing, which is a significant advantage for speeding up reporting of results.
However, this comes at the cost of increased contamination risk, as is the case with
most direct DST approaches. Additionally, the need for inverted microscopes (cost
about $1000[49], and are not part of standard laboratory setting), highly trained
personnel for result determination, which is also highly subjective, weigh up to the
cons of this rapid method.

CRI and NRA results were 96.7% and 93.3% concordant with those of MGIT
and MODS and, two of the validly tested samples were smear-negative. The
performance of CRI is more established by virtue of the existing body of literature
although more large scale studies in the target populations are needed. As for the
presented NRA format, there is limited data, and further testing is warranted by the
potential advantages. These include high specificity to MTB, shorter overall
turnaround time, and immediate result generation after indicator addition. The use of a
liquid-media based approach would positively affect TAT and ease of performance, as
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solid media for use in NRA have to be prepared in-house. Although this is a process
typically familiar to laboratory staff in limited-resource areas, which also may have a
cost advantage over buying ready commercial reagent, this is a lengthy laborintensive procedure, and reproducibility of batches would be a concern. Additionally,
there is an uncertainty regarding actual drug potency when incorporated in LJ media,
particularly that loss of potency may occur due to the high temperature used during
inssipation [11, 110]. Actually, this one reason why the egg-based LJ medium is not
regarded as suitable for DST, along with possible interference of its components with
drug activity. Even for the reference proportion method, OADC-supplemented
Middlebrook 7H10 agar is recommended medium by the CDC and CLSI [11]. A
collateral advantage is the fact that the indicator Griess reagent kills the mycobacteria
[11], thus reducing biohazard risk during documentation and disposal, albeit this does
not indicate any change in the standard biosafety measures. Despite the availability of
a tube version of NRA utilizing liquid culture, we opted for the optimization of a
microplate format. This allows handling of smaller culture volumes while allowing
for MIC determination and increasing throughput as multiple samples can be tested in
the same plate, which is more manageable and easier to handle in the restricted space
of a biosafety cabinet. Both assays utilize non-propriety reagents, and do not require
any specialized or costly equipment. This is an important advantage for areas with
low infrastructure and unstable power supply where sophisticated equipment like the
MGIT 960 system cannot be reliably maintained. Table 14 compares the cost and
infrastructure requirements for the 4 methods used in this study.
The evaluated colorimetric assays fit in between the performance of
conventional solid culture-based DST and the sophisticated cutting edge molecular
assays, with regards to cost, simplicity, and turnaround time. At the same time, they
offer reliable DST results. Capacity building for TB-afflicted regions, especially
HBCs would require substantial time and resources to reach up to the recommended
and desired DST, and is also affected by multiple factors beyond the medical scope
e.g. political and economic environment. Therefore, CRI and NRA are suitable tools
for the interim phase, as supported by WHO endorsement.

Establishment of breakpoint concentrations that reflect clinically significant
drug resistance is an important process, yet it is no simple feat and requires MICs
distribution analysis of the target population [37, 118]. Thus, a point that must be
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noted with regards to results interpretation is the fact that the used protocol for CRI
breakpoint concentration to designation of an isolate as drug resistant were ≥0.25
µg/mL for INH, and ≥0.5 µg/mL for INH, which was also used to NRA. However,
this was established based on testing of the study population. One isolate (#361)
showed a clear degree of resistance by CRI with MIC of 0.125 µg/mL, which is below
the standard break point. However, given that all drug-sensitive isolates did not
demonstrate any mycobacterial growth under the same assay conditions. Although
this isolate had to be considered to have a discordant result by CRI and NRA under
the used cutoffs, it may actually be considered to be intermediately resistant. Such a
determination and it clinical relevance is to be assessed by a larger scale study on the
Egyptian population.

5.2. Molecular characterization of clinical isolates
Multiple alignment using Align X of the Vector NTI 11.5 software package of the
sequenced 16S rDNA revealed polymorphisms at positions 513, and 526 of rrs were
found in three samples, two of which have been found to be SM resistant by MGIT.
Mutations at these locations, in general the region around nucleotide 530 (table 4),
(clinical frequency 2% for position 526) have been shown to be correlated with
resistance to SM, and degree of resistance may also be relevant [119-122]. Samples
#314 and #321 are streptomycin resistant according to MGIT results from NAMRU-3,
however, no data on MIC are available. Therefore exact correlation with MIC cannot
be determined, although current information in the literature correlates rrs with low to
moderate resistance [21, 123]. Mutations related to SM resistance in the rrs gene (16S
rDNA) are actively being studied in the current literature.
On the resistance front, the two MDR sample for which katG and rpoB were
sequenced demonstrated common high-confidence resistance-conferring mutations,
none of which were observed in the drug-susceptible strains. The observed mutations
are consistent with those commonly described in the literature (table 4). Also, they
are consistent with those which were found to be of highest frequency in studies
performed on Egyptian samples [124-125]. As for the INH monoresistant sample
#361, the lack of mutations in either katG or inhA, combined with the observed
discrepancy between its MGIT and MODS results and those of CRI and NRA, may
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suggest either the presence of mutations in other uncommon genes or that there is a
different origin of the phenotypic resistance such as an efflux mechanism.
Finally, on a general note, one of the important, yet underestimated, factors to
consider in method evaluation is the prior familiarity of the person performing the
evaluation of the method. Higher performance indicators are typically reported when
the method is evaluated by its industry or original developer, and about 40% of
studies on diagnostics of TB, HIV, and malaria encompass industry association of
some sort [114]. This creates a hidden bias, and in this study, the fact that the operator
had no prior familiarity with TB DST, or the tested methods, offers a fairly true
assessment of their degree of applicability and trainability in new settings.
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6. Conclusions and Future Perspectives
This study has evaluated the performance of low-cost rapid TB DST colorimetric
methods; CRI and NRA in Egypt, a moderate-resource setting. Both assays
demonstrated highly concordant results with reference methods and rapid TAT. Also,
their cost estimates (exclusive of labor and overheads) are around $5 (for testing an
isolate for 2 drugs with MIC determination) (table 14) versus MGIT cost per test $3256 (test only at critical drug concentrations) [49]. It is also to be noted that the cost of
NRA can be further reduced by preparing the Griess reagent in-house as opposed to
using a readymade commercial preparation as was done in this study. This
performance indicates suitability for use in reference laboratories with limited
resources, without the need for extensive staff training or equipment. Additionally,
result documentation is much simpler when compared to MODS.
The evaluated assays, CRI and NRA, provide low cost, relatively low
complexity, rapid indirect phenotypic DST. These assays are best suited for use in
central laboratories in resource poor areas with high TB prevalence. The use of
colorimetric detection adds to saving in both number and training of laboratory
personnel. Reading simplicity would increase number of sample reads per technician,
who also require only basic training, as opposed to MODS which requires specially
trained personnel for cording pattern detection and plate reading. Also, subjectivity in
result reading is minimized in color-based detection, which would only pose a
problem in case of the reading being performed by color-blind individual [83].
Another advantage of these colorimetric assays is the possibility of
quantification of mycobacterial load, as the indicator color is reflective of the amount
of viable mycobacteria [97]. This can be done either spectrophotometrically, or more
simply by computer analysis of the image taken of the plate. Considering that both
indicators; resazurin and Griess reagent, yield a degree of pink color, the image can be
analyzed for RGB content using any of the basic image editing software, freely
available on computer. A simple basic computer code can also be specially designed.
This is an upgrade of the assays that is to be pursued.
The primary limitation of this study is the number of samples and expansion
of this study to include a larger number of Egyptian patients is warranted. Also, a
larger proportion of the samples is to be MDR so as to further explore he prevailing
resistance-conferring mutations. The mutations are to be correlated with the
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subsequent degree of phenotypic resistance, which would aid disease detection and
control efforts. This is taking into consideration the possibility of MTB strain
heterogeneity in Egypt, indicated by the two clustering patterns obtained from the
analysis of the 16S rDNA of 10 out of the 34 samples (figure 22). The lack of data on
Egyptian strains, except an unexpected high proportion of Manu lineage [43], warrant
such an investigation. Additionally, for proper large scale implementation of CRI and
NRA and accurate clinically relevant interpretation of their results, MICs for resistant
Egyptian isolates are to be analyzed. They are then to be used to verify whether the
currently used breakpoint concentrations are suitable for the target population or if
their modification is warranted.
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7. Tables
Table 1. Egypt TB statistics. [3, 126]
Parameter
Incidence
Prevalence

Number/Percentage
Year
18 per 100,000, estimated total of 2010
15,000 cases
28 per 100,000, estimated total of 2010
23,000 cases

Mortality

less than 1 per 100,000, estimated
660 cases
Case detection rate
64%
% of MDR-TB in new cases
2.2%
% of MDR-TB in retreatment 38%
cases
Estimated cure rate (among 72%
new smear-positive pulmonary
cases)
% of notified new TB cases 1%
tested for MDR:
Total number of confirmed 204
MDR-TB among new and
retreatment patients
Number of smear laboratories
0.4 per100,000 population
Number of DST laboratories
less than 0.1 per 5 million population

43

2010
2010
2010
2010
2009

2009
2009

2010
2010

Table 2. Definitions of key terms related to drug resistance of tuberculosis.
Term
Definition
Reference(s)
Primary drug Resistance to a drug which is detected in an [24, 127]
resistance
isolate from a patient who has not previously
received, or has received less than one month of
drug therapy
Acquired drug Resistance to a drug which is detected in an [21, 24]
resistance
isolate obtained from a patient actively
undertaking antimyobacterial therapy or has
previously been treated.
Multi-drug
Resistance of an isolate to both RIF and INH
[24, 30]
resistance
(MDR)
Drug-resistant
An isolate is generally considered resistant to a [24]
isolate
given drug if more than 1% of the bacteria
exhibit resistance to that drug (applies to the
majority of anti-TB drugs).
Minimum
The first concentration of the drug that prevents [101]
inhibitory
isolate’s growth and change of indicator color.
concentration
(MIC)
Critical
A single concentration calibrated as midway [24, 123]
concentration
between the highest and lowest MICs of
different wild type strains, which is defined as
the concentration which kills 95% or more of the
wild type bacteria, not previously exposed to a
drug. It is used as a cut off in qualitative drug
susceptibility assays.
Direct DST
DST performed on primary clinical specimens [58]
without prior bacterial culturing.
Indirect DST
DST performed on pure isolates cultured from [58]
primary clinical specimens
DST: drug susceptibility testing; INH: isoniazid; MIC: minimum inhibitory
concentration; RIF: rifampicin; TB: tuberculosis
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Table 3. Main first-line TB drugs, mode of action, biochemical description, and resistance conferring mutations [21, 25-26, 46].
Drug

Isoniazid
(INH)

Rifampicin
(RIF)

Ethambutol
(ETH)

Streptomycin

Description

Mode of Action

Administration
Method

Utility in Treatment

Main Possible Adverse
Effects

Molecular
Basis of
Resistance
Mutations in
inhA, katG

Isonicotinylhydrazine,
a prodrug which is
transformed to the
active form by the
catalase peroxidase
enzyme of the
bacteria
A macrocyclic lipidsoluble antibiotic
which is a
semisynthetic
raifamycin derivative.

Interferes with the
enzymatic synthesis of
mycolic acid.

Mainly oral, but in the Bactericidal affecting critically ill, it may be actively replicating
injected
bacilli only.
intramuscularly
or
intravenously.
-

Systemic or
cutanous
hypersensitvity early
in treatment.
Lethargy
Neuropathy

Disruption of DNA
synthesis, by binding to
the  subunit of the
RNA polymerase.

Gastrointesitnal
reactions.
Pruritus without
rash.
Exfoliative
dermatitis is more
often encountered
with HIV patients.

Mutations in
rpoB

[(2S,2’S)-2,2’(ethylenediimino)1,2-diyldiimino)di-1butanol],

Interferes with
biosynthesis of the
MTB cell wall
components
arabinogalactan, and
lipoarabinomannan.

Dose-dependent
optic neuritis,
normall reversible.
Occasional
peripheral neuritis in
legs.

Mutations in
embB

Aminoglycoside

Interferes with mRNA

Oral, and possibly Bactericidal, affects
intravenous for the both
replicating
critically ill.
bacteria and those
with low metabolic
rates.
Both
intracellular
and
extracellular bacilli
are potently sterilized
by RIF.
Oral.
Bacteriostatic agent
effective only on
actively
growing
bacilli. It is used with
other first-line TB
drugs
to
delay
emergence
of
resistance.
Deep intramuscular
Killing actively

Injections are

Mutations in
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-

-

-

-

(SM)

antibiotic

translation by binding to injection. Also,
the 30S ribosomal
available for
subunit and the thus
intravenous injection.
inhibits bacterial protein
synthesis.

replicating bacteria,
but has no effect on
intracellular and nonreplicating bacteria
-

-

Pyrazinamide
(PZA)

Synthetic
nicotinamide
analogue, which is a
prodrug converted by
MTB to the active
compound
pyarazinoic acid.

Disrupts membrane
potential of MTB and
causes cytoplasmic
acidification by drawing
in protons.

Oral.

Potent sterilization
activity aimed
particularly at
intracellular bacilli in
the low pH
environment with
macrophages. It is
also weakly
bactericidal. Its
sterilizing effects
allow shortening of
treatment duration.
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-

painful, and rash or
rpsL and rrs
sterile abscesses may
appear at the
injection site.
Numbness around
the mouth right after
the injection.
Possible cutaneous
hypersensitivity.
Nephrotoxicity
Gastrointestinal
Mutations in
reactions.
pncA
A degree of hyper
uricemia.
Hepatotoxicity.

Table 4. Molecular basis of resistance to first-line anti-TB drugs [21, 119-120, 123, 128].
Drug

Isoniazid
(INH)

Rifampicin
(RIF)

Ethambutol
(ETH)
Streptomycin
(SM)

Pyrazinamide
(PZA)

Most Commonly
Normal Gene
Mutated Gene(s)
Product/role
in Resistant
Strains (mutation
target region)
inhA
Enoyl-acyl carrier
(regulatory region) protein reductase

Relative
Frequency in
Resistant Strains

Typical
Association with
Phenotypic
Resistance

6-30%

Moderate to
high level
resistance
Low level
resistance
Dependant on
specific
mutation, but
mostly high
level resistance
Low to moderate
level resistance
High level
resistance

katG
(entire gene)
rpoB
(81 bp hotspot
region)

Catalase/peroxidase

embB
(many codons)
rpsL
(codons 43 and
48)
Rrs

Arabinosyltransferase 47-89%

pncA
(many codons)

-subunit of RNA
polymerase

50-95%
90-95%

Ribosomal protein
S12

40-95%

16S rRNA

N/A

Pyrazinamidase
responsible for
conversion of the
prodrug to active
form

62-97%

Moderate level
resistance
Mostly high
level resistance
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Typical MICs
(Test Media)

Common High
Confidence
Mutations

>1 mg/L

Nucleotide (-)15

0.02–0.2
mg/L(7H9/7H10)
0.05–0.1 mg/L
(7H9/7H10)

Codon 315

1–5 mg/L
(7H9/7H10)
2–8 mg/L
(7H9/7H10)
N/A

Codon
516,Codon 531
(Ser531Leu, His
526Tyr,
His526Asp)
Codon 306

Mutation
Frequency

6-30%

50-95%
30-75%
(54%, 11%,
7%)

20-70%

rpsL 42 Arg, rpsL 88%, <1%,
42 Thr, rpsL 42
<1%
Asn
rrs 523 C, rrs 522 6%, 3%, 2%
T, rrs 526 T

16–50 mg/L (LJ)
N/A

N/A

Table 5. Main diagnostic strategies for TB infection.
Test
Smear examination

Detected marker
TB bacilli

Advantages
Limitations
Reference(s)
- Simple.
- Variable sensitivity (20-80%).
[3, 11, 30, 129]
- Cheap.
- Not very useful in patients with low
- Good specificity, particularly in TB
sputum bacillary load e.g. children and
endemic areas.
HIV patients.
- Highly dependent on skill of smear
examiner.
Tuberculin skin test
Antibody response to - Simple.
- Variable specificity.
[2-3]
TB proteins
- Cheap.
- Can give false positive results with
- Suitable for detection of latent
vaccinated individuals or previous
infection.
exposure.
Cellular
immune - Limited
infrastructure
and - Ineffective
in
case
of
severely [2-3, 58]
Interferon--release
response to
TB
equipment required.
immunocompromised individuals or the
assays
infection
- Moderate personnel training needed.
very young.
- Good specificity to MTB.
- Useful for use with BCG-vaccinated
individuals.
Liquid and solid culture TB bacterial growth
- High specificity.
- Complex.
[3]
- Can be adapted for determination of - High personnel training required.
drug sensitivity.
- Costly infrastructure and consumables
required.
Nucleic acid tests (e.g. TB bacterial DNA
- High specificity and sensitivity.
- High equipment and consumables cost.
[3, 30, 130]
PCR, real-time PCR,
- Fast.
- Extensive staff training and expertise
SDA, LAMP, LPAs)
- Decreased contamination risk in
needed
case of real-time PCR.
BCG: Bacillus Calmette–Guérin; LAMP: loop-mediated isothermal amplification; LPAs: line probe assays; PCR: polymerase chain reaction, SDA: strand
displacement amplification
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Table 6. Performance parameters for notable commercial phenotypic DST systems
System
Bactec 460
(BD Diagnostic
Systems, MD,
USA)
Bactec MGIT
960
(BD Diagnostic
Systems, MD,
USA)

Media
Middlebrook
7H12 broth

BacT/Alert MB
(bioMeriuex, NC,
USA)

Modified
Middlebrook
7H9 broth

Middlebrook
7H9 broth

Basis of growth detection
Detection of mycobacteria growth by detecting
14
CO2 liberated by actively growing bacteria from
14
C-labeled palmitic acid in the modified
MiddleBrook 7H12 broth
An oxygen-quenched fluorophore (tris 4, 7diphenyl-1, 10-phenonthroline ruthenium chloride
pentahydrate,) is embedded in the bottom of the
culture tube. As the bacteria grows and the oxygen
is consumed the fluorescence signal increases. The
automated system reads out the tubes
automatically, while in the manual version the
tubes are scanned using a UV light and positive
growth is indicated by orange fluorescence. In
DST fluorescence in the drug containing tubes is
compared with that of the drug-free growth tube to
determine positive growth and thus resistance in
the drug tube.
A colorimetric sensor is incorporated in the
medium which measures the production of carbon
dioxide by the growing mycobacteria, and growth
is indicated by change in color of indicator from
green to yellow.
The system monitors pressure changes in the
headspace of the culture vial, generated by the
mycobacterial metabolic activity.

VersaTrek (Trek Enriched
Middlebrook
Diagnostic
7H9 broth
Systems, OH,
USA) [formerly
known as the ESP
Culture System II]
 FDA approved. DST: drug sensitivity testing; TAT: turnaround time.
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DST (Drugs)
First-line

DST TAT
9.3 days

References
[24]

First-line. Some
studies also
indicate possible
use with ofloxacin
and kanamycin

-

DST TAT: 5-14 days after
primary isolation, where TAT
for TB detection is 4-13 days.

[47, 49,
131]

-

A sample is declared negative
after 42 days of no growth.

First-line

6-8 days

[24, 65]

First-line

4-8 days

[65, 132]

Table 7. Commercial molecular assays for MTB detection and drug susceptibility testing.
Assay
 COBAS® Amplicor®
MTB Test
(Roche Diagnostics,
Switzerland)

Samples
Pulmonary
specimens

Assay principle
PCR amplification of 584 bp fragment of 16S
rRNA gene. the biotin labeled amplicon is then
hybridized to MTBC specific probes coated to
microtiter plate, followed by colorimetric
detection.

Target
16S rDNA

Analytical Performance




COBAS® TaqMan® MTB
Test
(Roche Diagnostics,
Switzerland)

Pulmonary
specimens

Real-time PCR reaction for the amplification
of genus specific region of 16S rRNA gene.
The amplicon is detected by genus specific
Taqman® probes

16S rDNA


AMPLIFIED MTD
(Mycobacterium
Tuberculosis Direct) Test
(Gen-Probe,, CA, USA)

Pulmonary
specimens

The test qualitatively detect MTBC rRNA by
utilizing Transcription-Mediated Amplification
(TMA) for amplification of genus specific 16S
rRNA target and Hybridization Protection
Assay (HPA) for chemiluminescent detection
of amplified targets.

16S rDNA

Cultured
isolates

The test utilize nucleic acid hybridization
technique and HPA for the identification of
Mycobacterium isolated from cultures

16S rDNA

 AccuProbe
MYCOBACTERIUM
Culture Identification Test
(Gen-Probe, CA, USA)
INNO-LiPA
MYCOBACTERIA v2
(Innogenetics,
Ghent,
Belgium)

Solid
and
early Liquid
culture

A reverse hybridization assay. First
biotinylated primers are used to amplify 1623S spacer region. The biotinylated amplicon
is then hybridized with specific
oligonucleotide probes immobilized on
membrane based strips in parallel lines.

16S-23S rDNA spacer
region








Smear-positive samples:
Sensitivity: 96.9 %
Specificity:100%
Smear-negative samples:
Sensitivity: 79.5 %
Specificity: 98.7 %
TAT: 2.5 hrs after sample preparation
Smear-positive samples:
Sensitivity: 92-100%
Specificity:>95%
Smear-negative samples:
Sensitivity: 40-93%
Specificity:>95%
TAT: 2.5 to 3.5 hrs
Sensitivity: 99.2%
Specificity: 99.9%
TAT: 2-3 hrs after growth of isolates




Sensitivity: 100%
Specificity: 94.4%
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Smear-positive samples:
Sensitivity: 97%
Specificity:>95%
Smear-negative samples:
Sensitivity: 40-73%
Specificity:>95%
TAT: 6.5 hrs

References
[51, 68,
133]

[133]

[51, 134135]

[136-137]

[51, 138]

INNO-LiPA Rif.TB
(Innogenetics,
Gent,
Belgium)

Solid
and
early liquid
culture

Following hybridization color is developed
using alkaline phosphatase labeled streptavidin
and the substrate to develop purple/brown
color at positive bands.
The test principle is the Same as INNO-LiPA
MYCOBACTERIA v2.

rpoB





GenoType® MTBC
(Hain Lifescience, Nehren,
Germany)

Culture

GenoType MTBDRplus
(Hain Lifescience, Nehren,
Germany)

Sputum
culture

or

Amplification of RNA isolated from sample
by) technique (NASBA). Finally the amplified
product is hybridized membrane based strip in
a reverse hybridization approach
The test include three steps, DNA extraction
from clinical specimen or cultured material
(solid or Liquid) followed by multiplexed
amplification with biotinylated primers. The
biotin labeled amplicons are then hybridized to
membrane bound probes.

23S rRNA

rpoB
katG
inhA












Xpert MTB/RIF
(Cepheid Inc., CA, USA)

Sputum

Automated real-time PCR targeting specific
resistance related regions.

rpoB

Smear-positive samples:
Pooled sensitivity: 93%
Pooled specificity: 83% (reports range from 80 to
100%)
Smear-negative samples:
Pooled sensitivity: 65%
Pooled specificity: 96%
TAT: <2 hrs
Estimated cost per test $15-45
Sensitivity: 92%
Specificity: 100%
TAT: 5 hrs

[49, 51,
55, 139]

MTBC detection
Sensitivity: 94.4%
RIF resistance
Sensitivity: 96.2%
Specificity: 90.2%
INH resistance
Sensitivity: 97.3%
Specificity: 83.3%
TAT: 1-2 days
Estimated cost per test $15-45

[49, 52,
68, 139140]



Smear-positive samples:
Pooled sensitivity: 98%
Pooled specificity: 99%
 Smear-negative samples:
Pooled sensitivity: 75%
Pooled Specificity: 99%


TAT: 6-48 hours

 FDA approved. HPA: Hybridization protection assay; INH: isoniazid; NASBA: Nucleic Acid Sequence Based Amplification; RIF: rifampicin.
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[49, 68]

[49, 55]

Table 8. Comparison of different non-commercial phenotypic drug susceptibility assays for M. tuberculosis.
Assay
Slide DST

Medium
Liquid

Sample
Sputum

TAT/Cost
-

Advantages
Simplicity.
Safety

-

10 days
Thin layer agar

E-Test

Middlebrook
7H10 or 7H11
agar

Pulmonary and
extrapulmonary
specimens

Agar

Isolate

Middlebrook
7H9 broth

Simple requirements of
agar and conventional light
microscope.

-

-

Rapid resistance detection
within 5-10 days.
MIC determination.
Speed and possible direct
detection.
Low cost

-

13 days

5-10 days
MODS*

-

Sputum or
isolates

-

CRI (using
resazurin
indicator)*

Middlebrook
7H9 broth

Isolates

-

TAT: 7-9 days
Cost per
test $1.3 to 3.5

-

TAT: 8 days.
Pooled
sensitivity
97% for INH,
and 98% for
RIF.
Pooled
specificity
98% for INH,
99% for RIF.
Demonstrated
suitability for

-

-
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-

-

MIC determination.
Sample throughput is high.
Simple reading and
interpretation.

-

Limitations
Valid only for
sputum positive
cases.
No available
controls.
A CO2 incubator is
required.

References
[65, 84]

Requires very high
inoculum
concentration
Special personnel
training needed.
Highly subjective
to readers’ skills.
False-resistance
chances are high
due to
misidentification of
artifacts as TB
cords.
Biosafety concern
over repeated
opening of the
culture plate.

[65]

[55, 65,
84, 94]

[49, 65,
141]

[47, 64,
79, 97,
142]

NRA*

-

LJ

Sputum or
isolates

-

Middlebrook Sputum or
7H9 broth
isolates

both first and
second-line
drugs.
- Cost $3.75 per
sample per
drug
Combined for
direct and indirect
testing:
- Sensitivity
97% for both
INH and RIF
resistance
- Specificity
99% for INH
and 100% for
RIF resistance
- Cost $3-4
Direct Testing:
- Sensitivity
100% for both
INH and RIF
- Specificity
99.2% INH
and 99.3% for
RIF
- Cost about
$3.7 per
isolate for
indirect test at
critical drug
concentration.

-

Direct rapid testing.
Ease of result reading

-

Possible falsesusceptibility
results with rare
nitrate reductasenegative strains.

[49, 64]

-

MIC determination with
increased throughput.
Ease of result reading.
MTB specificity.

-

Possible falsesusceptibility
results with rare
nitrate reductasenegative strains.

[81, 108109]

-

*Assay sensitivity and specificity for MODS, CRI, and LJ-based NRA are based on WHO multicenter studies [64].
CRI: colorimetric redox indicator assay; INH: isoniazid; MODS: microscopic observation drug susceptbility; NRA: nitrate reductase assay;
RIF: rifampicin; TAT: turnaround time
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Table 9. PCR primers used for amplification of resistance-related genes.
Gene

Forward Primer

inhA

TCCACACCCTGCGGCA
CGTA
TTGACCTCCCACCCGA
CTTG
CAGACCACGATGACCG
TTCC

katG
rpoB

Reverse Primer

Annealing Amplicon
Temp.
Length
(°C)
(bp)
TGGCGTTGATGACCTT 51
590
CTCG
AGCTCGTATGGCACC 51
620
GGAAC
GAGCCGATCAGACCG 50
443
ATGTT
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Reference

--[116]
[117]

Table 10. Samples results by MODS and MGIT.

Resistance pattern
INH monoresistant
RIF monoresistant
MDR (INH + RIF resistant)
Sensitive

No. of Samples
3
1
5
25
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Table 11. CRI clinical performance (N=31)
Drug
Isoniazid

Sensitive Resistant Sensitivity Specificity
24/24
6/7
100%
96%

PPV
NPV
85.7% 100%

Rifampicin

26/26

5/5

100%

100%

100%

100%

drugs 23/23

4/4

100%

100%

100%

100%

Both
(MDR)
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Table 12. NRA clinical performance (N=30).
Resistance type
Isoniazid

Sensitive
23/23

Resistant
6/7

Sensitivity
85.7%

Specificity
100%

PPV
100%

NPV
95.8%

Rifampicin

24/25

5/5

100%

96%

83.3%

100%

Both drugs (MDR)

22/22

4/4

100%

100%

100%

100%
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Table 13.Mutations observed in the sequenced resistance-related gene region of isolates demonstrating phenotypic resistance.
Sample #

Phenotypic Resistance

314

INH
RIF
SM
ETH

344

INH
RIF

Gene
inhA

Position
---

--Codon 315

rpoB

AGCACC
(Ser  Thr)
TCGTTG (Ser Leu)

inhA

---

katG

AGCACC
(Ser  Thr)
CACTAC (HisTyr)

katG

rpoB
inhA
361

Observed Mutation
(Amino Acid Change)

INH

rpoB
katG
ETH: ethambutol; INH: isoniazid; RIF: rifampicin; SM: streptomycin; wt: wild type
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---------

Codon 531
--Codon 315
Codon 526
----------

Table 14. Comparison between the cost and infrastructure requirements of MGIT, MODS, CRI, and NRA [65, 87].
MGIT

MODS

CRI

NRA

Special equipment
needed

Yes

Yes

No

No

Propriety reagents

Yes

No

No

No

Operator training
requirements

Moderate

High

Low

Low

DST Cost per isolate for
both RIF and INH

$32-56 [49]

$1.4-3.5[49]

$4.5 (this study)

$5.2 (this study)

Laboratory
infrastructure

Advanced

Regular

Regular

Regular

Throughput

Very high (up to 960
samples per run)

Moderate

High

High

MIC determination

No

No

Yes

Yes

CRI: colorimetric redox indicator assay; DST: drug susceptibility testing; INH: isoniazid; MGIT: Mycobacterial Growth Indicator
Tube; MIC: minimum inhibitory concentration; MODS: microscopic observation drug susceptbility; NRA: nitrate reductase assay;
RIF: rifampicin.
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8. Figures

Figure 1. Estimated worldwide TB incidence rates in 2010. Reprinted from [3].
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Figure 2. Structure of mycobacterial cell wall. Reprinted from [143].
The exceptional high content of mycolic acid and peptidoglycan in the cell wall is the origin of the acid-fastness property of MTB.
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Figure 3. Global distribution of percentage of MDR-TB cases among newly notified TB cases. Reprinted from [34].

62

Figure 4. M. tuberculosis evolutionary scenario and geographical spread.“The main migrations events are numbered and
correspond to: 1, M. prototuberculosis, the ancestor of the MTBC, this bacterium reached the Fertile Crescent some 40,000 years ago
by sea or land; 2 and 3, two distinct basal lineages arose, EAI and LAM and spread out of Mesopotamia some 10, 000 years ago; 4, 5
and 6, later on (8–5000 years ago) derived populations from clade 1 followed main human migration patterns to Africa, Asia and
Europe, giving rise to locally adapted tubercle strains and further diversifications” Reprinted from [40].
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Figure 5. Chemical structures of first-line anti-TB drugs. A) Rifampicin, B) Isoniazid, C) Streptomycin, D) Ethambutol, E)
Pyrazinamide. Reprinted from [144].
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Figure 6. Action of different drugs in treatment of TB infection. Each drug targets the bacteria at a different metabolic states, to
ensure killing of all bacteria in the body. Reprinted from [48].
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Figure 7. Acid-fast staining of MTB bacilli in sputum (x1000 magnification) [12].

66

Figure 8. Colonies of MTB on LJ medium [145].

67

Figure 9. MODS plate layout. The samples are incubated with 7H9-supplemented broth in 24-well microplates. For each sample two
well contain each of the drugs at critical concentration and the other two do not and act as growth control. The plate is then sealed and
incubated at 37º C for a week and then examined under an inverted microscope. Reprinted from [92].

1

Figure 10. Characteristic cord-like appearance of MTB under the microscope in
MODS (20x). Reprinted from [146].
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Figure 11. CRI overview. Samples are incubated in broth with a serial dilution o f the
drugs in 96-well microtiter plate. The plate is then incubated for 7-10 days at 37 ºC, and
then a redox indicator is added e.g. resazurin or 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT). The plate is then reincubated overnight and then the
plate is observed for color change of the indicator reflecting bacterial growth. Successful
bacterial growth in drug-containing wells indicates bacterial resistance to that drug.
Reprinted from [79].
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Figure 12. Chemical structure of resazurin.
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Figure 13. Reaction of Griess indicator used in nitrate reductase assay. A
diazotization reaction is employed in the assay where sulphanilic acid reacts with nitrite
to form a diazonium salt intermediate, which then reacts with N-(1naphthyl)ethylenediamine to form the pink azo dye. The color formation indicates the
presence of viable bacteria converting the nitrate in the media to nitrite, where the latter
reacts with the Griess reagent to form the colored product [147].
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Figure 14. CRI plate layout. Two columns are dedicated to each sample, and each
column contains a serial dilution of each drug (I  isoniazid, R rifampicin). Blank (B)
controls containing only media are included for sterility check, and duplicate growth
controls (GC) are also included for each sample and contain only the sample and media
without drugs.
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Figure 15. NRA plate layout. Two columns are dedicated to each sample, and each
column contains a serial dilution of each drug (I  isoniazid, R rifampicin). Blank (B)
controls containing only media are included for sterility check, and duplicate growth
controls (GC) are also included for each sample and contain only the sample and media
without drugs.
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Figure 16.Typical CRI plate result. Mycobacterial growth is detected by change of
indicator color from blue to pink. GC is the growth control. Results of this plate are:
sample 410 is sensitive to both drugs, sample 428 is resistant to both drugs (MDR),
sample 326 is sensitive to both drugs, and sample 331 is sensitive to both drugs.
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Figure 17.Example of NRA plate result. Mycobacterial growth is detected by change of
indicator color from very faint pink to deep or reddish pink. GC is thegrowth control.
Results of this plate are: 6 is RIF-resistant, H37Rv is sensitive to both drugs. Sample 428
and 430 failed to show growth in the control wells . These samples were retested.
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A

B

Figure 18. Alignment results for forward (A) and reverse (B) primers for
amplification of 16S rDNA region using Vector NTI 11.5 software.
The alignment shows the high degree of conservation of the chosen region throughout
Mycobacterium genomes.
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Figure 19. Agarose gel electrophoresis result for the 16S rDNA amplion. The band
at~500 bp matches the expected amplicon size.
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Figure 20. Part of the16S rDNA sequencing result for sample #314. The peaks are
clear and sharp peaks and background noise is low.
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Figure 21. Blast analysis results for sample #314. This confirms sample identity as
Mycobacterium tuberculosis.
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Figure 22. Alignment of 16S rDNA sequences. The alignment shows high homology
between 8 out of the 10 sample while the remaining two are partially homologous.

81

Figure 23. Dendrogram for relationship between samples based on 16S sequencing.
Two samples clustered away from the remaining samples indicating possible strain
difference.
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Figure 24. Alignment 16S rDNA for samples demonstrating phenotypic resistance to
streptomycin. Two samples show mutations at positions 513 and 526 (E. coli
numbering).
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Figure 25. Alignemnt of katG sequences with marked mutations in codon 315. These
marked mutations are known to confer resistance to INH and the two samples in which
they were detected are phenotypically MDR, resistant to both INH and RIF.

84

Figure 26. Alignment of rpoB sequences with marked mutations in codons 526 and
531(E. coli numbering). These marked mutations are known to confer resistance to RIF
and the two samples in which they were detected are phenotypically MDR, resistant to
both INH and RIF.
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